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In Brief
Tumor-associated neutrophils (TANs)
have mainly been portrayed as tumor-
promoters. Here, we describe a novel
antitumor pathway in which TANs
promote IL-12 production by
macrophages, leading to type 1
polarization of a subset of unconventional
ab T cell (UTCab). Type 1 UTCab possess
an innate-like phenotype and antitumor
potential in vivo. In selected human
tumors, neutrophil infiltration is
associated with type 1 immunity and
better clinical outcome.
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https://doi.org/10.1016/j.cell.2019.05.047SUMMARY
Neutrophils are a component of the tumor microenvi-
ronment and have been predominantly associated
with cancer progression. Using a genetic approach
complemented by adoptive transfer, we found that
neutrophils are essential for resistance against pri-
mary 3-methylcholantrene-induced carcinogenesis.
Neutrophils were essential for the activation of an
interferon-g-dependent pathway of immune resis-
tance, associated with polarization of a subset of
CD4 CD8 unconventional ab T cells (UTCab). Bulk
and single-cell RNA sequencing (scRNA-seq) ana-
lyses unveiled the innate-like features and diversity
of UTCab associated with neutrophil-dependent
anti-sarcoma immunity. In selected human tumors,
including undifferentiated pleomorphic sarcoma,
CSF3R expression, a neutrophil signature and
neutrophil infiltration were associated with a type 1
immune response and better clinical outcome.
Thus, neutrophils driving UTCab polarization and
type 1 immunity are essential for resistance against
murine sarcomas and selected human tumors.
INTRODUCTION
Neutrophils are the most abundant cell type in human peripheral
blood and represent the first line of defense against invading mi-346 Cell 178, 346–360, July 11, 2019 ª 2019 The Authors. Published
This is an open access article under the CC BY license (http://creativecroorganisms (Kolaczkowska and Kubes, 2013). Neutrophils
play an important role in the activation and orchestration of acute
inflammatory reactions (Borregaard, 2010; Ley et al., 2018).
Moreover, neutrophils have emerged as important players in
the regulation of innate and adaptive immunity and in chronic
inflammation (Mantovani et al., 2011; Nicola´s-Avila et al., 2017).
Neutrophils are present in the tumor microenvironment (TME)
and their function is regulated by signals produced by cancer
cells and immune cells (Coffelt et al., 2016; Eruslanov et al.,
2017; Ponzetta et al., 2017). Neutrophils and the myeloid growth
factor granulocyte-colony stimulating factor (G-CSF) have pre-
dominantly been associated with tumor progression (Coffelt
et al., 2016; Wculek and Malanchi, 2015). On the other hand, un-
leashed neutrophilic effectors have also been reported to
mediate anti-cancer resistance (Colombo et al., 1991; Finis-
guerra et al., 2015; Fridlender et al., 2009; Granot et al., 2011;
Massara et al., 2018; Sagiv et al., 2015; Singhal et al., 2016).
For instance, neutrophils have been shown to regulate the func-
tion of conventional CD4+ andCD8+ tumor-infiltrating T cells with
activating or suppressive effects, thus influencing tumor growth
(Mantovani et al., 2011; Nicola´s-Avila et al., 2017). In addition to
conventional T cells, neutrophils can also modulate the activa-
tion of gd T cells, regulating their interleukin (IL)-17A production
in cancer (Coffelt et al., 2015).
Available evidence on the role of neutrophils in carcinogenesis
and tumor progression is essentially based on antibody-medi-
ated cell depletion (Coffelt et al., 2015; Fridlender et al., 2009;
Granot et al., 2011; Ponzetta et al., 2017). Given the intrinsic lim-
itations of this approach including duration, specificity, and
perturbation of the system (Faget et al., 2018; Granot et al.,by Elsevier Inc.
commons.org/licenses/by/4.0/).
A B C
Figure 1. Neutrophils Mediate Resistance to 3-MCA-Induced Sarcomagenesis
(A and B) Tumor (A) incidence and (B) growth of 3-MCA induced sarcomas in Csf3r+/+ and Csf3r/ mice.
(C) Tumor growth of 3-MCA-induced sarcoma in Csf3r+/+ and Csf3r/ mice upon adoptive transfer of neutrophils (NF) in Csf3r/ mice. 3 3 106 BM NF were
intravenously (i.v.) transferred once a week (time points indicated by arrows) starting from the first day the tumor was palpable. Tumor growth is represented as
volume over time after the first tumor observation.
Data are mean ± SEM (A and B) or mean ± SD (C). *p% 0.05, ***p% 0.001. (A and C) Wilcoxon matched-pairs signed-rank test.
See also Figures S1 and S2 and Table S1.2011; Moses et al., 2016), we set out to assess the role of neutro-
phils using a genetic strategy and a classic model of 3-methyl-
cholanthrene (3-MCA)-induced carcinogenesis (Bonavita et al.,
2015; Kaplan et al., 1998; Shankaran et al., 2001). We took
advantage of genetic deficiency of G-CSF-R, a strategy analo-
gous to that used to dissect the role of tumor-associated macro-
phages (TAMs) (Lin et al., 2001).
Unexpectedly, we found that neutrophils mediate resistance
against primary carcinogenesis. Neutrophil-driven antitumor
resistance was dependent on interferon-g (IFNg) produced by
T cells. Neutrophil deficiency was associated with a selective
impairmentof type1polarizationand IFNgproductionbyasubset
of unconventional CD4CD8 ab T cells (UTCab). As assessedby
flow cytometry and single-cell RNA sequencing (scRNA-seq) an-
alyses, UTCab were present in the sarcoma TME and were func-
tionally regulated by neutrophils. Neutrophil infiltrationwas found
to be associated with better prognosis and higher IFNG expres-
sion in human undifferentiated pleomorphic sarcomas (UPS)
and in selected tumors. Thus, in murine sarcomas and selected
human tumors, neutrophils are an essential component of type
1 antitumor immunity. More in general, the role of UTCab in anti-
tumor immunity may have been underestimated.
RESULTS
Neutrophils Mediate Resistance against Primary 3-MCA
Sarcomagenesis
Genetic deficiency of the G-CSF-R (Csf3r/) caused a profound
neutropenia in the peripheral blood of healthy mice (Figure S1A)
(Liu et al., 1996). In the 3-MCA-induced sarcomamodel,Csf3r/
mice showed earlier tumor development and increased tumor
growth and weight, compared to wild type mice (Figures 1A,
1B, and S1B). The increased susceptibility of Csf3r/ to
3-MCA carcinogenesis was consistently observed in 20 experi-
ments conducted over a period of 4 years, although as expected
for primary carcinogenesis, with variability from experiment
to experiment (6 experiments are shown in Figures 1A and
S1C–S1G).Dysbiosis is known to impact on carcinogenesis and anti-tu-
mor responses (Zitvogel et al., 2015). However, cohousing did
not affect sarcoma susceptibility (Figure S1H), excluding that
a potential dysbiosis associated with Csf3r deficiency was
involved in the observed phenotype.
In bone marrow chimeras, increased susceptibility to sarco-
magenesis was associated with G-CSF-R deficiency in hemato-
poietic cells and neutrophil depletion by an anti-Ly6G antibody
accelerated tumor development (Figures S1I and S1J). Adoptive
transfer of bone marrow Csf3r+/+ neutrophils (purity >98.5%)
(Figure S1K) into Csf3r/ sarcoma-bearing mice was sufficient
to completely rescue tumor growth to the level of Csf3r+/+ con-
trols (Figure 1C). Collectively, these results provide unequivocal
genetic evidence that neutrophils mediate protection against pri-
mary 3-MCA sarcomagenesis.
Tumor-Associated Neutrophils in Csf3r+/+ Mice Display
an Activated Phenotype
The number of CD45+ cells infiltrating the tumor was similar in
Csf3r/ andCsf3r+/+ mice (Figure S2A). Tumor-associated neu-
trophils (TANs) were virtually absent in Csf3r/ tumors (Figures
S2B and S2C). In Csf3r+/+ sarcoma-bearing mice, TANs dis-
played an activated phenotype, characterized by increased
expression of CD11b and CD54 and decreased expression of
CD62L, compared to peripheral blood neutrophils (Figures
S2D–S2F). mRNA expression of pro-inflammatory genes such
as Cxcl10, Il23a, Arg1, Nos2, Ccl2, Ifng, Ccl3, Met, and Il27p28
in sorted TANs was increased, compared to naive bone marrow
neutrophils (Figure S2G). Thus, TANs presented a mixed pheno-
type expressing both N1-like (e.g., CD54, Ccl3, Nos2, and Met)
and N2-like (e.g., Arg1 and Ccl2) markers (Finisguerra et al.,
2015; Fridlender et al., 2009).
Neutrophil Deficiency Is Associated with Altered
Polarization of Tumor-Associated Macrophages
The number of TAMs was significantly increased in Csf3r/
mice (Figures S2B and S2C). The increased frequency of TAMs
in Csf3r/ mice was associated with increased proliferationCell 178, 346–360, July 11, 2019 347
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Figure 2. Neutrophils Mediate Tumor Resistance by Inducing a Macrophage-Dependent Activation of Type 1 Immunity
(A) Il12a and Il12bmRNA expression (normalized on fluorescence minus one [FMO]) in myeloid cells infiltrating the 3-MCA injection site, analyzed by PrimeFlow
RNA assay.
(B and C) IFNg (B) and IL-12p70 (C) concentrations at the 3-MCA injection site (10 days after 3-MCA administration) after treatment with anti-CD115 antibody or
isotype control.
(D and E) IFNg (D) and IL-12p70 (E) concentrations in tumor homogenates after adoptive transfer of 33 106 neutrophils once a week starting from the first day the
tumor was palpable. (D) and (E) are two independent experiments conducted 12 months apart.
(F) Incidence of 3-MCA induced sarcomas in Csf3r+/+ and Csf3r/ mice treated with anti-iFNg antibody or with isotype control.
(A–E) Data are mean ± SEM. *p% 0.05, **p% 0.01, ***p% 0.001. (A) two-tailed multiple Student’s t tests. (B–E) One-way ANOVA. (F) Friedman test with Dunn’s
multiple comparison test.
See also Figure S2 and Table S1.observed in monocytes and immature macrophages (Fig-
ure S2H). In G-CSF-R-incompetent mice, monocytes and
TAMs showed increased expression of the M2-associated
marker CD206 and decreased expression of the M1-associated
marker CD11c (Figures S2I–S2K), likely a reflection of defective
type 1 immunity (see below). Gene expression analysis on sorted
TAMs confirmed the increased expression of M2-like-related
genes (Murray et al., 2014), including Chil3, Tgfb1, and Msr1,
in Csf3r/-derived TAMs, while the expression of M1-related
geneswas either notmodulated or decreased (Figure S2L). Intra-
tumor vessel density was not altered in Csf3r/ mice (Figures
S2M and S2N).
The G-CSF-R is expressed by monocytic lineage cells,
although to amuch lower extent compared to neutrophils (Chris-
topher et al., 2011). However, G-CSF did not affect macrophage
polarization by classical M1 or M2 signals (IFNg and IL-4), and if
anything, it skewed these cells in an M2-like direction (Figures
S2O–S2R).
Therefore, the M2-like phenotype found in Csf3r/ TAMs is
due to the absence of neutrophil-dependent response and not
to lack of G-CSF-R signaling in the monocytic lineage.348 Cell 178, 346–360, July 11, 2019Neutrophils and Macrophages Cooperate to Promote an
IFNg-Dependent Antitumor Response
Macrophages obtained during 3-MCA carcinogenesis in G-CSF-
R-competent mice expressed IL-12 and those from Csf3r/
mice displayed reduced Il12a and Il12b mRNA expression (Fig-
ure 2A). These results raised the issue of the role of TAMs in
the increased susceptibility of Csf3r/ mice to 3-MCA carcino-
genesis. As shown in Figures S2S and S2T, TAM depletion using
an anti-CSF-1R (CD115) monoclonal antibody (mAb) did not
rescue the phenotype of G-CSF-R-deficient mice, consistently
with an essential role of neutrophils. Interestingly, TAM depletion
increased carcinogenesis in G-CSF-R competent mice (Fig-
ure S2T) and drastically reduced the tissue levels of IL-12p70
and IFNg (Figures 2B and 2C). As shown in Figures 2B–2E and
Table S1, the increased sarcoma development observed in
Csf3r/ neutrophil-deficient mice was associated with lower
levels of IL-12p70 and IFNg. Neutrophil adoptive transfer
restored the expression of IL-12p70 and IFNg in the TME of sar-
coma-bearingCsf3r/mice (Figures 2D and 2E). In vivo neutral-
ization of IFNg caused a dramatic increase of tumor incidence in
Csf3r+/+ mice as previously reported (Kaplan et al., 1998; Koebel
A B C
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Figure 3. Neutrophils Drive DNTab Type 1 Polarization
(A) Expression of IFNg by tumor-infiltrating T cells stimulated ex vivo by PMA plus ionomycin.
(B) Representative dot plot showing Rorgt, and T-bet expression in UTCab from Csf3r
+/+ and Csf3r/ tumors.
(C and D) Quantification of Eomes, Rorgt, and T-bet expression in UTCab from Csf3r
+/+ and Csf3r/ tumors (C) and in Csf3r/ mice after adoptive transfer of
neutrophils (D).
(E) Expression of Eomes, Rorgt, and T-bet in UTCab infiltrating the 3-MCA injection site (10 days after administration of 3-MCA).
(F) Quantification of iNKT, MAIT, and DNTab frequencies among sarcoma-infiltrating CD45
+ cells.
(G) Polarization of tumor-associated DNTab cells after neutrophil adoptive transfer.
(D and G) 33 106 neutrophils were transferred i.v. once a week starting from the first day the tumor was palpable. (E) 33 106 neutrophils were transferred i.v. at
days 1, 0, 1, and 9 with respect to 3-MCA administration. (A and C–G) Data are mean ± SEM. *p% 0.05, **p% 0.01, ***p% 0.001. (A, C, and F) Two-tailed
multiple Student’s t tests. (D) One-way ANOVA. (E and G) Kruskal-Wallis test with Dunn’s multiple comparison test.
See also Figures S3 and S4.et al., 2007; Shankaran et al., 2001), but not inCsf3r/mice (Fig-
ure 2F), abolishing the difference in sarcoma susceptibility be-
tween Csf3r+/+ and Csf3r/ control mice. These results indicate
that the protective effect exerted by neutrophils was dependent
on type 1 immunity and on the production of IFNg.
Neutrophils Are Essential for Type 1 Polarization of
Unconventional ab T Cells
Having established that IFNg played a key role in neutrophil-
mediated resistance to 3-MCA carcinogenesis, it was important
to identify the cellular source of this cytokine. Analysis of Ifng
mRNA indicated T cells as the major source of this cytokine in
the TME (Figure S3A). No difference was observed in IFNg pro-
duction in CD4+, CD8+, and gd T cells between Csf3r+/+ and
Csf3r/ mice (Figure 3A). In contrast, the frequency of IFNg+
CD4 CD8 unconventional ab T cells (UTCab) was drastically
reduced (by 61.3% ± 11.4%; mean ± SEM in 2 experiments) in
Csf3r/ tumors (Figure 3A). We then assessed the polarization
of tumor-infiltrating CD3+ T cell subsets by flow cytometry
(gating strategy in Figure S3B). UTCab from Csf3r
/ tumors dis-
played reduced expression of T-bet and Eomes and increased
expression of Rorgt, indicating a skewing toward a type 3 activa-
tion state (Figures 3B and 3C). A trend toward a skewed UTCabpolarization was also observed in the spleen of Csf3r/ tu-
mor-bearing mice, although to a minor degree compared to
sarcoma-infiltrating cells (Figure S3C). gd T cells from Csf3r/
sarcomas showed increased Rorgt expression, while Eomes
and T-bet expression was not altered in this cell type (Fig-
ure S3D). Minor or no differences were observed in conventional
CD4+ T cells and CD8+ T cells (Figure S3D). Neutrophil adoptive
transfer reversed to a significant extent the polarization defect
observed in UTCab from Csf3r
/ tumors (Figure 3D). Increased
T-bet expression was also observed in gd T cells and CD8+
T cells (Figure S3E). IL-17A expression was significantly in-
creased inCsf3r/UTCab and gd T cells, in agreement with their
increased expression of Rorgt (Figure S3F). Natural killer (NK)
cells are known to be important IFNg producers (Vivier et al.,
2018) and have been shown to undergo a functional conversion
toward ILC1 during sarcoma progression (Gao et al., 2017), but
no difference was observed in abundance or maturation state
of the NK cell compartment in Csf3r/ tumors (Figures S3G
and S3H).
Previous reports indicated that innate-like gd T lymphocytes,
represented an early source of IFNg during the 3-MCA-induced
sarcomagenesis (Gao et al., 2003). Here, the impaired type 1
activation state of UTCab was observed as early as 10 days afterCell 178, 346–360, July 11, 2019 349
3-MCA injection, while little or no differences were observed in
the polarization of gd and CD4+ T cells (Figures 3E and S3I).
The frequency of UTCab, gd T cells, and conventional CD4
+
T cells was not appreciably altered at the 3-MCA injection site
(Figure S3J). It should be noted that at early times (10 days after
3-MCA injection), CD8+ T cells were virtually absent (Figure S3J).
Bone marrow neutrophil transfer induced a complete rescue of
T-bet expression and partially reduced the expression of Rorgt
in Csf3r/ UTCab present at the 3-MCA injection site, as early
as 10 days after 3-MCA administration, indicating that neutro-
phils are an essential component of UTCab polarization early in
3-MCA-induced sarcomagenesis (Figure 3E). In contrast, the po-
larization of other T cell subsets was not affected by neutrophil
transfer at early time points (Figure S3I).
Csf3r/ UTCab expressed high levels of Plzf (Figures S4A and
S4B), a commonly expressed transcription factor in invariant nat-
ural killer T (iNKT) cells and mucosal-associated invariant T
(MAIT) cells (Koay et al., 2016; Kovalovsky et al., 2008). These
innate-like T cell subsets are also prevalently negative for CD4
andCD8 and can express Rorgt and T-bet (Cui et al., 2015; Engel
et al., 2016; Rahimpour et al., 2015). Dissection of intratumor
UTCab into MAIT, iNKT, and a third cell subset, referred to as ab
double negative T (DNTab) cells, showed the heterogeneity of
UTCab in 3-MCA-treated mice (Figures S4C and S4D). We found
increased frequencies of iNKT,MAIT, andDNTab cells inCsf3r
/
sarcomas, but only the polarization of DNTab cells was altered in
neutropenic mice (Figures 3F, 3G, S4E, and S4F). In the same
line, neutrophil adoptive transfer modulated the polarization of
DNTab cells but not iNKT and MAIT cells both at the early time
point (at the 3-MCA injection site, day 10) (Figures S4G–S4I)
and in established tumors (Figures 3G, S4E, and S4F). On day
10, the frequency of UTCab subsets was unaffected in Csf3r
/
mice (Figure S4J). The presence and polarization of UTCab sub-
sets were not altered in the subcutaneous tissue of healthy
mice (Figures S4K–S4N). Altogether, these data showed that
neutrophils specifically regulated the polarization of DNTab cells
at early and late time points during carcinogenesis.
Neutrophil-Dependent IL-12 Production Is Essential for
IFNg Expression in UTCab
In an effort to better characterize the features of UTCab associ-
ated with neutrophil-sustained anti-sarcoma type 1 immunity,
bulk RNA-seq analysis of sorted sarcoma-infiltrating UTCab
was performed. 95 genes were differentially expressed between
Csf3r+/+ and Csf3r/ UTCab (Figure 4A; Table S2). The expres-
sion of Il17a, Tbx21, Eomes, and Ifng genes in Csf3r/ UTCab
was in line with data obtained by flow cytometry at the protein
level with decreased expression of T-bet, Eomes, and IFNg
and increased expression of IL-17A (Figures 3A–3C and S3F). In-
genuity pathway analysis (IPA) highlighted the upregulation of
pathways involved in inflammatory responses and neutrophil
recruitment and downregulation of the pathway of Th1 immune
response in Csf3r/ UTCab (Figure S5A; Table S3). To identify
the signaling pathways specifically activated on cancer-associ-
ated UTCab, we compared the transcriptome of tumor-associ-
ated Csf3r+/+ UTCab with gd T cells and conventional CD4
+ and
CD8+ T cells and found 190 differentially expressed genes (Fig-
ure S5B; Table S2). The Ifng mRNA levels detected in UTCab350 Cell 178, 346–360, July 11, 2019isolated from Csf3r+/+ sarcomas were comparable to that
expressed by CD8+ and gd T cells (Figure S5C), indicating the
significance of UTCab-derived IFNg in the TME.
Upstream regulator analysis predicted the increased activation
of STAT4, IL-18, and IL-12 pathways in tumor-associated UTCab,
compared to other T cell subsets (Figure S5D; Table S3). qPCR
performed on splenic T cell subsets from untreated mice
confirmed the higher expression of Il12rb1, Il12rb2, Il1r5, and
Il1r7 in UTCab compared to conventional T cells (Figures 4B and
4C). Accordingly, UTCab produced higher IFNg levels in response
to IL-12 plus IL-18 stimulation, compared to other T cell subsets
(Figure 4D). In vivo IL-12p70 neutralization skewed the polariza-
tion of Csf3r+/+ UTCab to a T-bet
low phenotype (Figure 4E), while
no effect was observed in gd T cells (Figure S5E). Consistently,
signaling related to several type 1 cytokines in Csf3r/ UTCab,
including IL-12, were predicted to be significantly inhibited
compared to Csf3r+/+ UTCab (Figure 4F; Table S3).
The results discussed above suggest that in 3-MCA carcino-
genesis neutrophils, in concert with macrophages, trigger a pro-
tective type 1 response involving IFNg-producing UTCab cells. In
an effort to explore the cellular basis for this tripartite interaction,
an in vitro coculture system was set up. For these studies,
spleen-isolated UTCab, which are composed by more than
85% of DNTab cells, were used (Figure S5F). In an in vitro cocul-
ture model, neutrophils dramatically amplified IL-12 production
by macrophages in response to triggering by cytokines and
TLR9 agonist (Figure 4G) or, to a lesser extent, STING agonist
(Figure S5G), which mimic conditions of tissue damage and
remodeling. Neutrophil-mediated amplification was contact-
dependent (Figure 4G). The amount of IL-12 produced in this
experimental setting was sufficient to trigger IFNg production
by UTCab but not by CD4
+ and CD8+ conventional T cell popula-
tions isolated from the spleen of untreated control mice (Fig-
ure 4H). Importantly, upon exposure to relevant cytokines,
sarcoma-infiltrating DNTab cells are the most potent producers
of IFNg compared to other T cell subsets (Figure 4I). Collectively,
these data suggest that the neutrophil-mediated maintenance of
UTCab type 1 polarization is driven by their higher sensitivity to IL-
12 compared with other T cell populations.
Single-Cell RNA-Seq Analysis of Tumor-
Infiltrating UTCab
To dissect the diversity of tumor-associated UTCab subsets,
scRNA-seq was performed on sorted sarcoma-infiltrating
UTCab, isolated from Csf3r
+/+ (14,721 cells) and Csf3r/
(16,902 cells) tumors. scRNA-seq analysis revealed the tran-
scriptional complexity of the UTCab population. Unsupervised
clustering using Seurat methodology (Butler et al., 2018) allowed
the identification of 12 clusters (Figures 5A and 5B).
Each cluster was characterized by a specific gene signature,
associated to distinct effector functions, biological processes,
and activation states (Figures 5A and 5C; Table S4). Clusters
1–4 represented more than 75% of total UTCab and were differ-
entially enriched in Csf3r+/+ and Csf3r/ sarcomas (Figures 5A
and 5B). In particular, clusters 1 and 3 were enriched in Csf3r/
sarcomas (Figures 5A and 5B) and displayed pronounced
expression of genes compatible with MAIT cell phenotype
(e.g., Cxcr6, Rorc, Icos, Zbtb16) (Koay et al., 2016; Rahimpour
05
10
15
20
25
IF
N
+ 
(%
 o
f c
el
ls
)  
- N M N +MCM
*
*Isotype
anti-IL-12p70
N +M N +M
UTC CD4+ CD8+
Csf3r +/+ Csf3r -/-
Ifng
Tbx21
Eomes
Il17a
Eomes+ Ror t+ T-bet+
0
10
20
30
40
50
%
 o
f U
TC
  c
el
ls
Csf3r+/+ + isotype
Csf3r+/+ + anti-IL-12p70
Csf3r-/- + isotype
Csf3r-/- + anti-IL-12p70
ns
ns
p=0.1
*
ns
*
ns
*
ns
ns
**
***3-MCA 
injection site
A
B C
Gzmb
Nkg7
- IL12 IL18 IL12+IL18
0
10
20
30
40
IF
N
+  c
el
ls
 
(%
 o
f t
ot
al
 c
el
l s
ub
ty
pe
) CD4+  T
CD8+  T
UTC
 T
**
** *
*
*******
D E
Il12rb1 Il12rb2
0.00
0.04
0.08
0.12
R
el
at
iv
e 
ex
pr
es
si
on
 (2
^-
dC
t) CD4+  T
CD8+  T
UTC
 T
*** ***
*** ***
***
***
Il1r5 Il1r7
0.0
0.1
0.2
0.3
0.4
0.5
R
el
at
iv
e 
ex
pr
es
si
on
 (2
^-
dC
t) CD4+  T
CD8+  T
UTC
 T
***
****** ***
***
***
M N
M
 + 
N
M
 + 
N
 (tr
an
sw
ell
)
0
1
2
3
4
IL
-1
2p
70
 [n
g/
m
l]
*** ***
G H
CD
4
CD
8
MA
IT
iN
KT  T
DN
T
0
20
40
60
IF
N
+  c
el
ls
 
(%
 o
f t
ot
al
 c
el
l s
ub
ty
pe
s)
***
***
***
I
3.93E-10
7.53E-06
2.45E-18
3.53E-05
4.41E-06
1.16E-11
4.88E-06
2.10E-04
1.69E-04
4.58E-08
-4 -2 0 2 4
IL15
IL27
ITK
STAT1
IFNG
IL12
IL6
IL17A
SMAD3
STAT3
Activation z-score
U
ps
tre
am
 re
gu
la
to
r
F
Figure 4. IL-12-Dependent Polarization and IFNg Production Is Impaired in Tumor-Infiltrating UTCab from Csf3r
/ Mice
(A) Heatmap showing differential transcriptional profiles of Csf3r+/+ and Csf3r/ tumor-associated UTCab. Differentially expressed genes (p% 0.001) are shown
(arrows indicate genes associated with effector functions).
(B and C) mRNA expression of (B) Il12rb1 and Il12rb2 and (C) Il1r5 and Il1r7 in splenic T cell subsets isolated from untreated Csf3r+/+ mice.
(D) Expression of IFNg by splenic T cell subsets isolated from untreated Csf3r+/+ mice.
(E) Eomes, Rorgt, and T-bet expression in UTCab infiltrating the 3-MCA injection site after treatment with IL-12p70-neutralizing antibody or isotype control.
(F) Predicted upstream regulators in tumor-infiltrating Csf3r/ UTCab compared with tumor-infiltrating Csf3r
+/+ UTCab, generated by IPA analysis. Associated
p p value is shown for each regulator.
(G) IL-12p70 levels detected by ELISA in supernatants of BMDM-neutrophil cocultures after stimulation with GM-CSF+CpG.
(H) Expression of IFNg in naive splenic ab T cell subsets stimulated for 24 h with supernatants collected in (G) in the presence of IL-12p70-neutralizing antibody or
isotype control, assessed by flow cytometry.
(I) IFNg production from Csf3r+/+ sarcoma-infiltrating T cells upon stimulation with IL-2+IL-12+IL-18 for 24 h assessed by flow cytometry.
(B–I) Data aremean ±SEM. ***p% 0.001; **p% 0.01; *p% 0.05; ns, not statistically significant. (B–E and I) One-way ANOVA. (G andH) Two-tailed Student’s t test.
See also Figures S4 and S5 and Tables S2 and S3.et al., 2015) (Figures 5C and 5D; Table S4) andwith the type 3 po-
larization state of Rorgt+ DNTab cells (i.e., Tmem176a-b, Il17a,
Rorc) (Figures 5C and 5D). On the other hand, clusters 2 and 4
were enriched inCsf3r+/+ sarcomas (Figures 5A and 5B) and pre-
sented high expression of effector molecules (i.e., Gzmb, Ifng,
Tbx21) compatible with the type 1 activation state of T-bet+DNTab cells and genes related to Ly49 family (Klra1, Klra7,
Klra9) (Figures 5C and 5D). The relative frequencies of cell sub-
types obtained through flow cytometric analysis indicated a
complete quantitative overlap of Rorgt+ DNTab cells with cluster
1, MAIT cells with cluster 3, and T-bet+ DNTab cells with clusters
2 and 4 (Figures S5H–S5J). Cluster 5 displayed a gene signatureCell 178, 346–360, July 11, 2019 351
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related to iNKT cells (Table S4), in line with quantitative data from
flow cytometry analysis (Figure S5K). No expression ofCsf3rwas
detected in any Csf3r+/+ UTCab subset, thus excluding that lack
of G-CSF-R signaling in UTCab cells might impact on their polar-
ization and function (data not shown).
Correlation analysis performed on the whole transcriptome
highlighted the existence of twomain functionally distinct cluster
groups (Figure S6A), which mirrored the respective composition
of UTCab subsets in Csf3r
+/+ and Csf3r/ sarcomas. Gene set
variation analysis (GSVA) performed on differentially expressed
genes for each cluster showed the enrichment of IFNg signaling
and IL-12 signaling mediated by STAT4 in clusters enriched in
Csf3r+/+ sarcomas (clusters 2 and 4) (Figure S6B), in line with
data obtained by flow cytometry (Figure 3). Accordingly,
Il12rb2 expression was mainly confined to clusters 2 and 4 (Fig-
ure 5D), confirming their higher sensitivity to IL-12. These clus-
ters were also characterized by enrichment in gene signatures
associated with innate-like T cell activation and cytotoxic activity
(e.g., DAP12 signaling, TRAIL signaling, FasL signaling, and T
cytotoxic pathways) (Figure S6B).
To better characterize the 12 identified UTCab clusters and
their functional heterogeneity, we analyzed the gene expression
of molecules related to key biological pathways. In particular, we
assessed the enrichment of genes related to cell proliferation (Li
et al., 2019) (Figure S6C), cell migration (Zhang et al., 2018) (Fig-
ure S6D), costimulatory molecules and immune checkpoints
(Sledzinska et al., 2015), and effector molecules (Guo et al.,
2018) (Figures S6E and S6F). Cluster 11 represented the only
subset in active proliferation (Figure S6C). Clusters 1 and 3
were characterized by the expression of a specific set of immune
checkpoints (i.e., Icos, Sigirr, and Vsir) and chemokine receptors
(i.e., Cxcr6, Ccr1, and Ccr4). On the other hand, clusters 2 and 4
expressed several effector molecules (i.e., Gzmb, Gzmd, and
Prf1) and a different set of chemokine receptors and costimula-
tory molecules, including Cxcr3, Ccrl2, and Cd28 (Figures S6D–
S6F). Among the other UTCab subsets, cluster 12 expressed
genes related to functionally active, terminally differentiated
T cells (i.e., Gzmk, Gzma, S1pr5, Cx3cr1, and Pdcd1) (Figures
S6D–S6F), while cluster 9 was characterized by the expression
of migratory molecules typical of naive T cells such as S1pr1,
Ccr7, and Sell (Figure S6D).
Importantly, clusters 2 and 4 showed a specific enrichment of
NK cell-related genes, in particular those included in the Ly49
(Klra) and NKG2 (Klrc) receptor families (Figure 5E). We validatedFigure 5. scRNA-Seq Analysis of Tumor-Infiltrating UTCab
(A) t-Distributed stochastic neighbor embedding (t-SNE) projection showing Seura
2Csf3r+/+ (14,721 cells) and 2Csf3r/ (16,902 cells) sarcomas (see STARMethod
(left) or according to Csf3r+/+ and Csf3r/ conditions (right).
(B) Bar graph showing the relative abundance of each cluster in Csf3r+/+ and Cs
(C) Heatmap showing the top 10 differentially expressed genes in clusters 1–1
expression, red indicates higher expression. Expression scale is shown on the ri
(D) t-SNE projections showing the relative distribution of selected genes inCsf3r+
(E) Heatmap showing the expression of NK cell-related genes in sarcoma-infiltrati
dotted blue line highlights the enrichment of NK cell-related genes in clusters 2 a
(F) Expression of NK cell-related molecules on Csf3r+/+ sarcoma-infiltrating T ce
(G) Representative histograms of the analysis shown in (F).
(F) Data are mean ± SEM. ***p% 0.001. One-way ANOVA.
See also Figures S5 and S6 and Table S4.these findings by flow cytometry on sarcoma-infiltrating Csf3r+/+
T cells (Figures 5F and 5G).
Indeed, tumor-associated DNTab cells displayed a unique set
of Ly49 molecules (Figures 5F and 5G) and expressed higher
levels of CD94 and NKG2ACE compared to any other T cell sub-
set (Figures 5F and 5G).
A Monocle-guided transcriptional trajectory identified five
different functional states ordered along an artificial pseudotime,
in which the 12UTCab clusters were differentially distributed (Fig-
ures 6A and 6B). The trajectory was defined by a gene set that
included molecules related to T cell polarization (i.e., Tbx21
and Rorc), effector functions (i.e., Gzmb, Ifng, and Il17a), and
activation state (i.e., Nr4a1,3) (Figure S6G; Table S5). Interest-
ingly, type 3 polarized cells (clusters 1 and 3) and type 1 polarized
cells (clusters 2 and 4) were positioned at the opposite ends of
the trajectory and represent the extremes in a spectrum of func-
tional states (Figures 6A and S6G; Table S5). Importantly, the
expression of several Klra genes was dynamically regulated dur-
ing the trajectory and was higher in state 5 (Figures 6C and S6G).
A previously validated splenic NK cell gene signature (Crinier
et al., 2018) was significantly enriched in cells pertaining to state
5 (clusters 2 and 4), thus confirming their innate-like phenotype
(Figure 6D). Notably, splenic DNTab cells from untreated mice
showed an array of receptors analogous to that observed in tu-
mor-infiltrating DNTab cells (Figures 6E and 6F), suggesting
that the spleen might represent a Ly49+ DNTab cell reservoir.
Thus, these results provide insight into the diversity of tumor-
associated UTCab at a single-cell level and highlight a subset
of Ly49R-expressing UTCab (i.e., DNTab in clusters 2 and 4)
with type 1 polarization and potential antitumor activity.
In an effort to obtain an indication as to the actual antitumor
potential of DNTab cells, we conducted an in vivo cotransfer
model in two transplantable murine sarcoma models (MN-
MCA1 and FS6) (Bonavita et al., 2015). At low DNTab/tumor
cell ratios (1:5 and 1:20), DNTab cells significantly reduced tumor
growth (Figure 6G and 6H). Thus, DNTab cells can indeed
mediate antitumor resistance in vivo.
Neutrophil Infiltration Is Associated with Better
Prognosis and Type 1 Immunity in Selected Human
Tumors
The results reported above identify a novel neutrophil-orches-
trated pathway of effective type 1 immunity against sarcoma-
genesis. It was therefore important to explore its significance int-guided unsupervised clustering and distribution of 31,623UTCab pooled from
s). Each point represents a single-cell colored according to cluster designation
f3r/ sarcomas, colored according to cluster designation.
2. For each cluster, the average expression is plotted. Blue indicates lower
ght.
/+ and Csf3r/ UTCab cells. The position of clusters 1, 2, 3, and 4 are indicated.
ng UTCab cells. Clustering is based on their cluster-specific gene expression. A
nd 4.
ll subsets as assessed by flow cytometry.
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human disease. Human soft tissue sarcomas (STS) are a hetero-
geneous and complex set of neoplasias in terms of genetic ab-
normalities and clinical behavior, responsible for 5,000 deaths
per year in the United States (American Cancer Society, 2017;
Taylor et al., 2011). We interrogated the RNA-seq The Cancer
Genome Atlas (TCGA) database and found that in undifferenti-
ated UPS a type 1 immune response gene signature and IFN,
were associated with favorable outcome (Figures 7A and 7B;
Table S6). Moreover, CSF3R expression was also associated
with better outcome in terms of overall survival in UPS patients
(Figure 7C). Using a previously validated neutrophil-specific
gene signature (Bindea et al., 2013; Chao et al., 2016) (31 genes,
listed in Table S6), UPS patients were divided into TANhigh and
TANlow subgroups. The resulting Kaplan-Meier curve showed
that patients with TANhigh tumor biopsies at diagnosis had a sig-
nificant survival advantage compared to TANlow patients and a
trend was observed for recurrence-free survival (hazard ratio
[HR] 0.28; 95% confidence interval [CI] 0.07–1.16) (Figures 7D
and S7A). Interestingly, high CSF3R expression was associated
with a type 1 immunity signature and with IFNG expression (Fig-
ures 7E and 7F). No association was observed between CSF3R,
neutrophil signature, IFNG, or type 1 immune signature and
outcome in other sarcomas (i.e., dedifferentiated liposarcoma,
leiomyosarcoma and myxofibrosarcoma) (Figures S7B–S7M).
TAN infiltration in human UPS tumor specimens was validated
by immunohistochemistry for CD66b in a separate cohort of
19 UPS patients followed at Humanitas Clinical and Research
Center (Figure 7G; Table S7). The mean number of neutrophil
infiltration ranged from 1 to 17 cells per field (Figure 7G). Recur-
rence-free survival was higher in CD66bhigh UPS patients (Fig-
ure 7H). Interestingly UPS, which accounts for 14% of total
STS (Brennan et al., 2014), has been suggested to be the coun-
terpart of 3-MCA-induced sarcomas (Katenkamp et al., 1988; Li
et al., 2010).
We extended our analysis to other human cancer datasets and
found a significantly positive correlation between the neutro-
philic infiltrate, IFNG expression, a type 1 immune response
gene signature and better prognosis in colorectal cancer (CRC)
(Figures 7I–7L). Moreover, CSF3R was positively correlated
with IFNG expression (Figure 7M), suggesting that the neutro-
phil-IFNg axis might be relevant in selected human tumors.
Interestingly, high neutrophil infiltration assessed by immunohis-
tochemistry has previously been associated with better outcomeFigure 6. Ly49+ DNTab Cells Display an Innate-like Phenotype and Ant
(A) Monocle-guided cell trajectory orders five transcriptional states along an a
dark blue.
(B) Analysis of UTCab distribution along the transcriptional states described in (A).
states. Clusters are ordered according to their calculated pseudotime mean sco
(C) Representation of Klra gene expression plotted as a function of pseudotime.
(D) Violin plots showing the enrichment of a splenic NK cell gene signature describ
analysis. Mean Z score was calculated for each cell. Statistical significance was
(E) Expression of NK cell-related molecules on splenic Csf3r+/+ T cell subsets iso
(F) Representative histograms of the analysis shown in (D).
(G andH) In vivo cotransfer assay was performedwith sorted DNTab cotransferred
with either 2 3 106 FS6 cells (G) or 5 3 105 MN-MCA1 cells (H).
(E) Data are mean ± SEM or (G and H) mean ± SD. *p% 0.05, **p% 0.01, ***p% 0
comparison test.
See also Figures S5, S6, and S7.in CRC in five independent reports (Berry et al., 2017; Bindea
et al., 2013; Galdiero et al., 2016; Governa et al., 2017; Wikberg
et al., 2017). These results suggest that, mirroring findings in
3-MCA carcinogenesis, a neutrophil-type 1 immunity axis may
play a role in resistance against selected human tumors (Figures
7 and S7N–S7W), in particular UPS and CRC.
DISCUSSION
Evidence based on antibody-mediated depletion and on clinical
associations suggests that neutrophils can exert a dual influence
on carcinogenesis, progression to metastasis and response to
therapy (Coffelt et al., 2016; Engblom et al., 2017; Fridlender
et al., 2009; Galdiero et al., 2016; Granot et al., 2011; Massara
et al., 2018; Wculek and Malanchi, 2015). Here, we provide un-
equivocal genetic evidence based on Csf3r deficiency, sup-
ported by antibody-dependent depletion and adoptive cell
transfer, that neutrophils are essential for mounting an effective
type 1 IFNg-dependent immune response, which restrains
3-MCA sarcomagenesis.
T cells and IFNg have long been known to mediate resistance
against 3-MCA-driven carcinogenesis (Kaplan et al., 1998; Koe-
bel et al., 2007; Shankaran et al., 2001). Here, we report that
neutrophil deficiency was associated with a selective functional
skewing of UTCab cells with no discernable impact on the polar-
ization state of other T cell subsets. It remains unclear whether
the enhanced carcinogenesis observed in Csf3r/ neutrophil-
deficient mice is only a reflection of defective IFNg production,
increased skewing to a type 3 IL-17 response, or a combination
of the two. The discovery of a neutrophil/UTCab axis, relevant to
the control of mesenchymal carcinogenesis, raises the general
issue of the relevance of innate-like UTCab cells in cancer.
The neutrophil-dependent pathway of resistance to sarcoma
induction by 3-MCA involved IL-12 produced by macrophages.
In an in vitro coculture model, neutrophils dramatically amplified
macrophage-derived IL-12 release, which was sufficient to
trigger IFNg production by UTCab but not by CD4
+ or CD8+
T cells. This finding is reminiscent of a previously reported innate
lymphoid cell subset, characterized by a unique capacity to pro-
duce IFNg in response to IL-12 (Fuchs et al., 2013). Thus, in
3-MCA sarcomagenesis a tripartite interaction involving neutro-
phils, macrophages, and UTCab is an essential component of
type 1 immune resistance.itumor Activity In Vivo
rtificial pseudotime. Pseudotime is shown colored in a gradient from light to
Bar graphs represent the frequency of cells belonging to each cluster in the five
re (from low to high pseudotime).
ed in (Crinier et al., 2018) in the five transcriptional states identified by Monocle
calculated comparing state 5 with every other state.
lated from untreated mice, assessed by flow cytometry.
with two sarcoma cell lines. 105 DNTabwere co-injected (subcutaneously [s.c.])
.001. (D and E) One-way ANOVA. (G and H) Friedman test with Dunn’s multiple
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scRNA-seq analysis showed that tumor infiltrating UTCabwere
highly heterogeneous. Twelve clusters were identified, and four
of them represented over 75% of the total UTCab pool. These
clusters included cells with molecular signatures of MAIT cells.
Csf3r deficiency was associated with selective depletion of
DNTab cells belonging to clusters 2 and 4, characterized by a
gene expression repertoire indicative of antitumor effector func-
tion. These cells expressed several NK cell-related molecules,
such as Ly49 inhibitory receptors as well as CD94/NKG2A inhib-
itory complex. Ly49+ DNTab cells were present in the spleen of
untreatedmice andwere able tomediate antitumor activity in vivo
suggesting that the spleen might represent a reservoir of Ly49+
DNTab cells endowed with antitumor potential. Interestingly,
the targets of current checkpoint blockade therapies PD-1 and
CTLA-4 were not prominently expressed by these cells. Thus,
the present results suggest that in tumors in which there is evi-
dence for a neutrophil/IFNg resistance pathway, targeting DNTab
cell inhibitory receptors should be considered as an alternative
or complementary strategy. These results highlight for the first
time the presence, diversity, and antitumor potential of UTCab
in the TME and suggest that neutrophils can sustain the anti-
tumor potential of Ly49+ DNTab cells.
A type 1 immune response signature, IFNG, CSF3R, and a
neutrophil signature were associated with better survival in
selected human tumors, including UPS and CRC (Figures 7
and S7N–S7W). The finding of neutrophil infiltration being asso-
ciated with better outcome based on in silico analyses of public
databases was consistent with data obtained by immunohisto-
chemistry for UPS in the present report (Figures 7G and 7H)
and for CRC in five independent previous studies with large
case lists (Berry et al., 2017; Bindea et al., 2013; Galdiero
et al., 2016; Governa et al., 2017; Wikberg et al., 2017). These re-
sults strongly suggest that the neutrophil-dependent pathway of
antitumor resistance described in 3-MCA carcinogenesis is
indeed relevant in selected human tumors. This neutrophil-type
1 immunity axis may have broader significance in neoplastic
and non-neoplastic conditions.
The results reported here emphasize the diversity of mecha-
nisms of immune resistance in human tumors, even when histo-Figure 7. Neutrophils Are Associated With Better Prognosis and Type
Cancer
(A) Kaplan-Meier survival curve of UPS patients from TCGA cohort with respect
specimens.
(B) Kaplan-Meier survival curve of UPS patients from TCGA cohort with high or l
(C and D) Kaplan-Meier survival curves of UPS patients from TCGA cohort with h
tumor specimens.
(E and F) Relative expression of type 1 gene signature (E) and IFNG (F) in tumor sa
according to their high or low expression of CSF3R.
(G) Example of high and low neutrophil infiltration in human UPS assessed by histo
Clinical and Research Center stained with anti-CD66b antibody.
(H) Kaplan-Meier curve shows recurrence-free survival for UPS patients from Hu
(CD66bhigh and CD66blow assessed by immunohistochemistry).
(I–L) Kaplan-Meier survival curves of CRC patients stratified according to their
expression.
(M) Pearson correlation between CSF3R and IFNG expression in CRC patients.
(A–D and H–M) Numbers depicted in each graph represent the total number of p
(E and F) Boxes: 25–75 range; whiskers: 10–90 range. (E and F) ***p % 0.001. (A
U-test; HR, hazard ratio; CI, 95% confidence interval. (M) Pearson correlation.
See also Figure S7 and Tables S6 and S7.logically related, and call for tailoring of immunotherapy strate-
gies and correlate biomarkers, including neutrophil-related
ones, to the diversity of immune pathways. Moreover, the occur-
rence and significance of UTCab in the TME may have been
underestimated.STAR+METHODS
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reverse 50-CGT ACC GGA TGA GCT GTG AAT T-30
This Paper N/A
Ccl2: forward 50- ATT GGG ATC ATC TTG CTG GT-30
reverse 50- CCT GCT GTT CAC AGT TGC C-30
This Paper N/A
Arg1: forward 50- TTT TTC CAG CAG ACC AGC TT-30
reverse 50- AGA GAT TAT CGG AGC GCC TT-30
This Paper N/A
Tgfb1: forward 50-CAA CCC AGG TCC TTC CTA AA-30
reverse 50- GGA GAG CCC TGG ATA CCA AC-30
This Paper N/A
Il27p28: forward 50- AGC TCT TGA AGG CTC AGG
G-30 reverse 50- GTG ACA GGA GAC CTT GGC TG-30
This Paper N/A
Ifng: forward 50-TCA AGT GGC ATA GAT GTG GAA
GAA-30 reverse 50-TGG CTC TGC AGG ATT TTC
ATG-30
This Paper N/A
Il10: forward 50-GGT TGC CAA GCC TTA TCG GA-30
reverse 50-ACC TGC TCC ACT GCC TTG CT-30
This Paper N/A
Stab1: forward 50-CCC TCC TTC TGC TCT GTG TC-30
reverse 50- CAA ACT TGG TGT GGA TGT CG-30
This Paper N/A
Mrc1: forward 50-TGG CAT GTC CTG GAA TGA T-30
reverse 50-CAG GTG TGG GCT CAG GTA GT-30
This Paper N/A
Msr1: forward 50-TGC CCT CAT TGC TCT CTA CC-30
reverse 50- TTC ATT TCC CAA TTC AAA AGC TC-30
This Paper N/A
Il4ra: forward 50- GTG GAG CCT GAA CTC GCA-30
reverse 50-AAG CAC GCA GAT CCA AAA TC-30
This Paper N/A
Marco: forward 50-TTC TGT CGC ATG CTC GGT TA-30
reverse 50-CAG ATG TTC CCA GAG CCA CC-30
This Paper N/A
Met: forward 50-TGT CCG ATA CTC GTC ACT GC-30
reverse 50-CAT TTT TAC GGA CCC AAC CA-30
This Paper N/A
Il1b: forward 50- GGT CAA AGG TTT GGA AGC AG-30
reverse 50- TGT GAA ATG CCA CCT TTT GA-30
This Paper N/A
Ccl3: forward 50- GTGGAATCTTCCGGCTGTAG-30
reverse 50- ACCATGACACTCTGCAACCA-30
This Paper N/A
Cxcl10: forward 50-CCG TCA TTT TCT CCC TCA
TCC-30 reverse 50- CCC TAT GGC TGC TTC ACT
CTC A-30
This Paper N/A
Il23a: forward 50-AGC ATT TAT GCT TCC AAA GC-30
reverse 50-GGA GGT CTC AAG TTC CTA CAT G-30
This Paper N/A
Ccr3: forward 50-TGA AAC TGT GAT CTT GGG ACA-30
reverse 50-CAG CAT CAA CAA CAC GTT CC-30
This Paper N/A
Il1r5: forward 50-GAT GCA TGT TTA GGC TTC CA-30
reverse 50-TCT TCT GCT GTC TGG AGC AA-30
This Paper N/A
Il1r7: forward 50-AGA GTG CAG AGA GGC AAA CC-30
reverse 50-TGA AAC CCT CTT CCT CCA GA-30
This Paper N/A
Il12rb1: forward 50- GCA GCC GAG TGA TGT ACA
AG-30 reverse 50- GAG ACG CGA AAA TGA TGG AT-3
This Paper N/A
Il12rb2: forward 50- AAC ACC AGA GGA AGA GCC
TG-30 reverse 50- CGT CAC CTG ATA GTG GAG GA-30
This Paper N/A
Gapdh/GAPDH: forward 50-GCA AAG TGG AGA TTG
TTG CCA T-30 reverse 50-CCT TGA CTG TGC CGT
TGA ATT T-30
This Paper N/A
Software and Algorithms
FlowJo v9.3 FlowJo https://www.flowjo.com/solutions/flowjo/downloads
Prism v7 GraphPad https://www.graphpad.com
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
FastQC (v.0.11.6) FastQC http://www.bioinformatics.babraham.ac.uk/projects/
fastqc
STAR (v.020201) Dobin et al., 2013 https://github.com/alexdobin/STAR
edgeR (v.3.24.1) Robinson et al., 2010 http://bioconductor.org/packages/release/bioc/html/
edgeR.html
CellRanger (v.2.1.1) 10X Genomics https://support.10xgenomics.com/single-cell-gene-
expression/software/pipelines/latest/what-is-cell-
ranger
Seurat (v.2.3.4) Butler et al., 2018 https://satijalab.org/seurat/
Monocle (v.2.8.0) Trapnell et al., 2014;
Qiu et al., 2017
http://cole-trapnell-lab.github.io/monocle-release/CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Alberto
Mantovani (alberto.mantovani@humanitasresearch.it) or to Sebastien Jaillon (sebastien.jaillon@humanitasresearch.it).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
All mice used were on a C57BL/6J genetic background. Csf3r-deficient mice were purchased from the Jackson Laboratory, Bar
Harbour, Maine, US. All colonies were housed and bred in the SPF animal facility of Humanitas Clinical and Research Center in indi-
vidually ventilated cages. Mice were randomized based on age and weight.
Procedures involving animals handling and care were conformed to protocols approved by the Humanitas Clinical and Research
Center (Rozzano, Milan, Italy) in compliance with national (D.L. N.116, G.U., suppl. 40, 18-2-1992 and N. 26, G.U. March 4, 2014) and
international law and policies (EECCouncil Directive 2010/63/EU, OJ L 276/33, 22-09-2010; National Institutes of Health Guide for the
Care and Use of Laboratory Animals, US National Research Council, 2011). The study was approved by the Italian Ministry of Health
(approvals n. 334/2013-B, issued on 27/12/2013 and n. 261/2017-PR issued on 28/03/2017). All efforts were made to minimize the
number of animals used and their suffering. Inmost in vivo experiments, the investigators were unaware of the genotype of the exper-
imental groups.
Carcinogen-induced sarcoma model
Male mice were injected s.c. with a single dose of 100 mg of 3-MCA (Sigma-Aldrich, St Louis, US) dissolved in corn oil and assessed
for tumor development over the course of 5 months. Data are shown as tumor incidence and tumor volume according to the formula:
Volume = (Dxd2)/2, where D = larger tumor diameter and d = smaller tumor diameter, during the entire duration of the experiment
using a calliper. In neutrophil adoptive transfer experiments, tumor growth is expressed over time (days) after the first palpable tumor
observation (V = 4 mm3). In cohousing experiments, Csf3r+/+ and Csf3r/ male mice were cohoused in a 1:1 ratio from birth until
8 weeks of age, and then injected with 3-MCA.
Depletion and blocking experiments
For neutrophil and IFNg depletions, mice were intraperitoneally (i.p.) treated with 200 mg of specific mAbs (Rat anti-Ly6G, Clone 1A8;
Rat Isotype Control Clone 2A3; Rat anti-iFNg, Clone XMG1.2; Rat Isotype Control, Clone HRPN) on the day before 3-MCA admin-
istration, and with 100 mg twice a week for the entire duration of the experiment. In IL-12p75 depletion experiments, mice were i.p.
treated with 1 mg of Rat anti-iL-12p75 (Clone R2-9A5; Rat Isotype Control, Clone LTF-2) on the day before 3-MCA administration,
and with 500 mg on days +1 and +6 after 3-MCA administration. For M-CSFR blockade experiments mice were i.p. treated as pre-
viously shown (Hashimoto et al., 2011) with 1.5 mg of Rat anti-CD115 (Clone AFS98; Rat Isotype Control, Clone 2A3) on the day
before 3-MCA administration, and with 300 mg twice a week after 3-MCA administration until mice reached experimental endpoint.
In a second set of experiment, mice were i.p. treated with 1.5 mg on the day before 3-MCA administration and with 300 mg on days
0, +3 and +7 after 3-MCA administration. All depleting antibodies were purchased from Bioxcell (West Lebanon, US).
Neutrophil adoptive transfer
In a first set of experiments, 3x106MACS-enriched bonemarrow neutrophils (PurityR 97.5%) isolated from naiveCsf3r+/+ mice were
injected i.v. in Csf3r/ sarcoma-bearing mice, once a week, starting from the first visible observation of tumor occurrence (rangeCell 178, 346–360.e1–e11, July 11, 2019 e5
75-100 days after 3-MCA administration), until mice reached the experimental endpoint. In a second set of experiments, neutrophils
were injected in Csf3r/ mice on day 1, 0, 1 and 9 with respect to 3-MCA administration, and mice were sacrificed on day 10.
Generation of Bone Marrow Chimeras
Csf3r-competent and -deficient micewere lethally irradiated with a total dose of 900 cGy. 2 hours later micewere injected in the retro-
orbital plexus with 4x106 nucleated bonemarrow cells obtained by flushing of the cavity of a freshly dissected femur fromwild-type or
Csf3r-deficient donors. Recipient mice received gentamycin (0.8 mg/ml in drinking water) starting 10 days before irradiation and
maintained during 2 weeks. 8 weeks after bone marrow transplantation, mice were challenged with 3-MCA.
Sarcoma transplantable models
FS6 and MN-MCA1 cell lines were cultured in RPMI-1640 medium supplemented with 10% Fetal Bovine Serum (FBS) 1% L-Gluta-
mmine, 1% Pen/Strept. On the day of the experiment cells were detached with Tripsin/EDTA solution (Lonza, Basel, Switzerland),
washed twice in PBS/ and diluted in PBS/ before injection. Mice were anesthetized and shaved on the back, 2x106 FS6 or
5x105 MN-MCA1 were injected subcutaneously. In the in vivo cotransfer experiments cells were co-injected with FACS-sorted
1x105 DNTab cells isolated from spleen of healthy Csf3r
+/+ mice.
Undifferentiated pleomorphic sarcoma patients
Patients (n = 19) whose biological samples were included in the study gave their signed consent to donate the tissue remaining after
the diagnostic procedure. Human UPS surgical samples were collected from Humanitas Biobank (n = 19), upon approval by the Hu-
manitas Research Hospital Ethical Committee (authorization 609/17, issued on 18 December 2017). Informed consent was obtained
from all participants. Demographics and clinicopathologic features of recruited patients are described in Table S7.
METHOD DETAILS
Organ collection, digestion and flow cytometry analysis
Single-cell suspensions of sarcomas, blood, spleen and skin were obtained and stained. Sarcomas were manually disaggregated
and incubated with 0.1 mg/mL Type IV Collagenase (Sigma Aldrich) in PBS/ at 37C for 60 minutes. Cell suspensions from spleen
were obtained as previously described (Ponzetta et al., 2015). Dorsal skin samples from untreated mice and 3-MCA injection sites
were manually disaggregated and incubated with 0.35 mg/mL DNase (Roche, Basel, Switzerland) and 0.125 mg/mL Liberase TM
(Roche) in RPMI at 37C for 90 minutes. Before further procedures, cell suspensions from every organ were filtered using 70 mm
cell strainers (Corning, Corning, US). Extracellular staining was performed using a PBS/ buffer containing FCS 2%, EDTA 2mM
and NaN3 0.05%. Prior to any surface staining, cells were incubated with Aqua LIVE/Dead-405 nm staining (Invitrogen, Carlsbad,
US) or Live/Dead Fixable Dye eF780 (ThermoFisher, Waltham, US) and negative cells were considered viable. Then Fc blocking
reagent (Clone 24G2) was added to any cell suspension for 10 minutes at 4C. Finally, extracellular staining was performed, and
antibody mix was added to cell suspension for 20 minutes at 4C. The following murine antibodies were used: anti-CD45-BV605,
-BV650 or -PerCp-Cy5.5 (Clone 30-F11); anti-CD3e-PerCP-Cy5.5 or -APC (Clone 145-2C11); anti-CD45.2-BUV805 (Clone 104);
anti-CD19-PE, - PerCP-Cy5.5 or -eFluor450 (Clone 1D3); anti-NK1.1-APC, -PE, -PECF594 or -BV650 (Clone PK136); anti-CD11b-
BV421, -BV480, -BV786, -APCCy7, -FITC (Clone M1/70); anti-CD27-FITC, –APC-eFluor780 or PE-Cy7 (Clone LG.7F9); anti-CD4-
AlexaFluor700 (Clone RM 4-5) or -FITC (Clone H129.19); anti-CD8-PE, BV480 or -BV570 (Clone 53-6.7); anti-iFNg-Alexa700 or
-BV421 (Clone XMG1.2), anti-Ly6G-PECF594, -BUV395 (Clone 1A8), anti-Ly6C-FITC or –BV421 (Clone AL-21), anti-MHCII-PercP-
Cy5.5, -BV711 (Clone 2G9) or –FITC (Clone M5/114.15.2), anti-F4/80-PECy7 (Clone BM8), anti-CD103-PercP-Cy5.5 (Clone 2E7),
CD86-eF450 (Clone GL-1), anti-CD24-APCeF780 (CloneM1/69), anti-CD64-PE (Clone X54-5/7.1), anti-CD11c-AlexaFluor700 or
-PE (Clone HL3), anti-TCRb-BV711 (Clone H57-597), anti-TCRgd-BV421 or –PercP-Cy5.5 (Clone GL3), anti-T-bet-PE or –BV785
(Clone O4-46), anti-Eomes-AlexaFluor488 (Clone Dan11Mag), anti-Rorgt-PECF594 (Clone Q31-378), anti-PLZF-AlexaFluor674
(Clone R17-809), anti-CD54-PE (Clone 3E2), anti-CD49a-BV711 (Clone Ha31/8), anti CD49b-APC (CloneDX5), anti-KLRG1-
BV786 (Clone 2F1), anti-NKP46-BV421 (Clone 29A1.4), anti-Ly49F-BV421 (Clone HBF-719); anti-Ly49C-I-BV605 (Clone 5E6);
anti-Ly49A-BUV395 (Clone A1); anti-Ly49G2-BV480 (4D11), anti-NKG2A/C/E-BUV563 (Clone20d5); anti-CD94-BV650 (Clone
18d3); anti-CD62L-APC or –BV570 (MEL-14) from BD Bioscience (San Jose, US), ThermoFisher (Waltham, US), BioLegend (San
Diego, US) or Miltenyi Biotec (Bergisch Gladbach, Germany). Murine iNKT cells were detected using CD1d-APC tetramers loaded
with aGalCer (ProImmune, Oxford, UK), while murine MAIT cells were detected using MR1-BV421 or -PE tetramers loaded with
5-OP-RU (kindly provided by James McCluskey, University of Melbourne). To avoid non-specific tetramer binding, during MAIT
staining cells were pre-incubated with the irrelevant unconjugated tetramer MR1 loaded with 6-FP (as described in Corbett et al.,
2014; Rahimpour et al., 2015; Reantragoon et al., 2013). Foxp3/Transcription Factor Staining Buffer Set (ThermoFisher) was used
for intracellular staining of transcription factors and cytokines. Results are reported as frequency or as mean fluorescence intensity
(MFI) normalized on isotype control or fluorescence minus one (FMO). Cells were analyzed on LSR Fortessa (BD Bioscience), for
some experiments cells were analyzed on FACSymphony (BD Bioscience). Data were analyzed with FlowJo software (Treestar,
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PrimeFlow RNA Assay
PrimeFlow RNA Assay (ThermoFisher Scientific) was performed following manufacturer’s instructions. Briefly, a single-cell suspen-
sion was obtained from dorsal skin of 3-MCA-treated mice and stained for surface antigens as described above. After fixation and
permeabilization, il12a-AlexaFluor647-, il12b-AlexaFluor488- or actb-AlexaFluor647-conjugated target probes were added for hy-
bridization, that was performed at 40C for 2 hours. Signal amplification was achieved by adding PrimeFlow RNA Pre-Amp mix
for 1.5 hours at 40C and then PrimeFlow RNA Amp Mix for 1.5 hours at 40C.
In vivo EdU-based proliferation assay
EdU (5-ethynyl-20-deoxyuridine) was administered i.p. (0.5mg/mice) to 3-MCA-treated mice, 24 hours before sacrifice once they
reached the experimental endpoint (calculated tumor volume of 2000 mm3). A single-cell suspension was obtained and surface an-
tigen staining was performed. EdU staining was performedwith Click-iT EdUAlexaFluor647 FlowCytometry Assay Kit (ThermoFisher
Scientific) following manufacturer’s instructions.
Bone-marrow derived macrophages (BMDMs)
Mouse bone-marrow cells were isolated from femurs and tibiae ofCsf3r+/+mice and cultured at density of 1.5x106 cells/mL in RPMI-
1640 medium supplemented with 10% Fetal Bovine Serum (FBS) 1% L-Glutammine, 1% Pen/Strept, with 20 ng/mL of murine GM-
CSF or 25 ng/mL of murine M-CSF (both M-CSF and GM-CSF were purchased from Peprotech). Cells were washed with PBS and
medium replaced at day 2 and 5. BMDMswere stimulated on day 7with murine IFNg (20 mg/mL) or murine IL-4 (20 mg/mL), alone or in
combination with murine G-CSF (50 ng/mL). After 24 hours cells were lysed with Trizol for further mRNA quantification.
For co-culture experiments, GM-CSF-derived BMDMs were stimulated with GM-CSF (50 ng/mL), either alone or in combination
with CpG (250 nM) (Invivogen, San Diego, US) or STING agonist cAIMP (1 mg/mL) (Invivogen). In indicated conditions, BMDMs
were co-cultured with 3x105 FACS-sorted neutrophils for 24 hours. In transwell experiments neutrophils were added into the upper
compartment of a Transwell permeable support with 0.4 mm pore (Corning, NY, US). After 24 hours medium was collected and IL-
12p70 concentration was analyzed by ELISA.
Ex vivo functional assays
Tumor-infiltrating leukocytes were MACS-enriched using CD45 Microbeads (Miltenyi Biotec) according to manufacturer’s instruc-
tions, obtaining a purityR 85%. Enriched cells were cultured in RPMI-1640 medium supplemented with 10% Fetal Bovine Serum
(FBS) 1% L-Glutammine, 1% Pen/Strept and IFNg intracellular staining was performed upon 5 hours of treatment with Cell Stimu-
lation Cocktail 1X (ThermoFisher), using Foxp3/Transcription Factor Staining Buffer Set (ThermoFisher). BD GolgiPlugTM (containing
Brefeldin) was added 4 hours prior to intracellular staining.
Cytokines stimulation experiments were performed on MACS-enriched CD45+ Tumor-infiltrating leukocytes, that were previously
depleted of CD11b+ cells (CD11b Microbeads, Miltenyi Biotec). Enriched cells were stimulated with the indicated combinations of
IL-2 (Proleukin, Novartis) (10ng/mL), recombinant murine IL-12 (Peprotech, London, UK) (20 ng/mL), human IL-18 (MBL, Woburn,
US) (50 ng/mL) for 16 hours. BD GolgiPlugTM was added during the last 4 hours of stimulation. Intracellular staining was performed
as indicated before using Foxp3/Transcription Factor Staining Buffer Set (ThermoFisher).
Purified splenic T cells from healthy Csf3r+/+ mice at a concentration of 3x106 cells/mL were stimulated with recombinant murine
IL-12 (Peprotech, London, UK) (20 ng/mL) and/or human IL-18 (MBL, Woburn, US) (50 ng/mL) for 16 hours. BD GolgiPlugTM (con-
taining Brefeldin) was added during the last 4 hours of stimulation.
In a second set of experiment, purified splenic T cells from healthyCsf3r+/+ mice were cultured with conditionedmedium (CM) from
BMDMs and neutrophils co-cultures at a concentration of 3x106 T cells/mL. Rat anti-iL-12p75 (Clone R2-9A5; Rat Isotype Control,
Clone LTF-2) 20 mg/mL were added to the CM and incubated at 4C for 30 minutes, before the incubation with T cells. Cells were
incubated for 24 hours, and BD GolgiPlugTM was added during the last 4 hours of stimulation.
RNA purification
For qPCR experiments, total RNA was extracted using Trizol reagent (Invitrogen) following the manufacturer’s recommendations.
RNA was further purified using RNeasy Min-elute RNA isolation kit (QIAGEN, Hilden, Germany). For 30 mRNA sequencing experi-
ments, RNAwas purified withMaxwell 16 LEV SimplyRNACells Kit (Promega, Madison, US) usingMaxwell 16 Instrument (Promega).
Quantitative PCR
cDNA was synthesized using 2 mg of total RNA by reverse transcription using High Capacity cDNA archive kit (Applied Biosystems,
Foster City, US) and quantitative real-time PCR was performed using the SybrGreen PCR Master Mix (Applied Biosystems) in a
CFX96 TouchTM Real-Time PCR Detection System (Bio-Rad, Hercules, US). Data were analyzed with the D2CT method (Applied
Biosystems, Real-Time PCR Applications Guide). Data were normalized based on the GAPDH expression determined in the same
sample. Analysis of all samples was performed in duplicate. Primers were designed according to the published sequences and listed
as follows:
Retnla (Fizz1): forward 50-CCCTTC TCA TCTGCATCTCC-30, reverse 50-CTGGAT TGGCAAGAAGTTCC-30;Chil3 (Ym1): forward
50-TCT GGG TAC AAG ATC CCT GAA-30, reverse 50-TTT CTC CAG TGT AGC CAT CCT T-30; Ccl5: forward 50-TGC AGA GGA CTCCell 178, 346–360.e1–e11, July 11, 2019 e7
TGA GAC AGC-30, reverse 50-GAG TGG TGT CCG AGC CAT A-30; Nos2: forward 50-GCC ACC AAC AAT GGC AAT A-30, reverse
50-CGT ACC GGA TGA GCT GTG AAT T-30; Ccl2: forward 50- ATT GGG ATC ATC TTG CTG GT-30, reverse 50- CCT GCT GTT
CAC AGT TGC C-30; Arg1: forward 50- TTT TTC CAG CAG ACC AGC TT-30, reverse 50- AGA GAT TAT CGG AGC GCC TT-30;
Tgfb1: forward 50-CAA CCC AGG TCC TTC CTA AA-30, reverse 50- GGA GAG CCC TGG ATA CCA AC-30; Il27p28: forward 50-
AGC TCT TGA AGG CTC AGG G-30, reverse 50- GTG ACA GGA GAC CTT GGC TG-30; Ifng: forward 50-TCA AGT GGC ATA GAT
GTG GAA GAA-30, reverse 50-TGG CTC TGC AGG ATT TTC ATG-30; Il10: forward 50-GGT TGC CAA GCC TTA TCG GA-30, reverse
50-ACC TGC TCC ACT GCC TTG CT-30; Stab1: forward 50-CCC TCC TTC TGC TCT GTG TC-30, reverse 50- CAA ACT TGG TGT GGA
TGT CG-30; Mrc1: forward 50-TGG CAT GTC CTG GAA TGA T-30, reverse 50-CAG GTG TGG GCT CAG GTA GT-30; Msr1: forward
50-TGC CCT CAT TGC TCT CTA CC-30, reverse 50- TTC ATT TCC CAA TTC AAA AGC TC-30; Il4ra: forward 50- GTG GAG CCT
GAA CTC GCA-30, reverse 50-AAG CAC GCA GAT CCA AAA TC-30;Marco: forward 50-TTC TGT CGC ATG CTC GGT TA-30, reverse
50-CAG ATG TTC CCA GAG CCA CC-30; Met: forward 50-TGT CCG ATA CTC GTC ACT GC-30, reverse 50-CAT TTT TAC GGA CCC
AAC CA-30; Il1b: forward 50- GGT CAA AGG TTT GGA AGC AG-30, reverse 50- TGT GAA ATG CCA CCT TTT GA-30; Ccl3: forward 50-
GTGGAATCTTCCGGCTGTAG-30, reverse 50- ACCATGACACTCTGCAACCA-30; Cxcl10: forward 50-CCG TCA TTT TCT CCC TCA
TCC-30, reverse 50- CCC TAT GGC TGC TTC ACT CTC A-30; Il23a: forward 50-AGC ATT TAT GCT TCC AAA GC-30, reverse
50-GGA GGT CTC AAG TTC CTA CAT G-30; Ccr3: forward 50-TGA AAC TGT GAT CTT GGG ACA-30, reverse 50-CAG CAT CAA
CAA CAC GTT CC-30; Il1r5: forward 50-GAT GCA TGT TTA GGC TTC CA-30, reverse 50-TCT TCT GCT GTC TGG AGC AA-30; Il1r7:
forward 50-AGA GTG CAG AGA GGC AAA CC-30, reverse 50-TGA AAC CCT CTT CCT CCA GA-30; Il12rb1: forward 50- GCA GCC
GAG TGA TGT ACA AG-30, reverse 50- GAG ACG CGA AAA TGA TGG AT-30; Il12rb2: forward 50- AAC ACC AGA GGA AGA GCC
TG-30, reverse 50- CGT CACCTG ATA GTGGAGGA-30;Gapdh/GAPDH: forward 50-GCA AAG TGG AGA TTG TTGCCA T-30, reverse
50-CCT TGA CTG TGC CGT TGA ATT T-30.
30-mRNA Sequencing
Tumor-infiltrating CD4+, CD8+, UTCab and gd T cells from Csf3r
+/+ and Csf3r/ sarcomas were FACS sorted (quadruplicates for
Csf3r/ and for Csf3r/ mice), and RNA was prepared as described above.
Total RNA extracted frompurified T cell subsets were subjected to Poly(A) mRNA sequencing. Libraries were constructed using the
SMART Seq v4 Ultra Low Input RNA kit according to manufacturer’s instruction (Illumina, San Diego, US). Sequencing was per-
formed with the NextSeq 500 (Illumina). All libraries were sequenced in single-end mode (75bp length).
Single-cell RNA sequencing
UTCab sorted populations in Csf3r
/ and Csf3r+/+ mice were subjected to single-cell RNA sequencing analysis. Two biological rep-
licates for each condition (Csf3r/ and Csf3r+/+) were analyzed. Single cell suspensions of cells have been prepared by tissue
mincing and enzyme digestion. FACS-sorted UTCabwere countedwith an automatic cell counter (Countess II, Thermo Fisher). UTCab
were loaded into one channel of the Single Cell Chip A using the Single Cell 30 reagent kit v2 (10X Genomics) for gel bead emulsion
generation. Following capture and lysis, cDNA was synthesized and amplified for 14 cycles following the manufacturer’s protocol
(10X Genomics). 50 ng of the amplified cDNAwere then used for each sample to construct Illumina sequencing libraries. Sequencing
was performed on the NextSeq500 Illumina sequencing platform following 10x Genomics instruction for reads generation. We recov-
ered a total number of 15,137 cells from Csf3r+/+ and 17,388 cells from Csf3r/ samples. An average sequencing depth of 20,000
reads/cell was recovered for each sample we processed. Cells with a null Cd3e unique molecular identifier (UMI) count were not
considered further for the analysis, resulting in a total number of 31,623 cells (14,721 cells for Csf3r+/+ and 16,902 cells for
Csf3r/ samples).
Purification of murine leukocytes
Bone marrow neutrophils were MACS-enriched with Neutrophil Isolation Kit (Miltenyi Biotec) according to manufacturer’s instruc-
tions for adoptive transfer experiments. Purity of neutrophils was > 98% as determined by flow cytometry.
For in vitro co-cultures experiments MACS-enriched neutrophils were stained for LiveDead-Fixable Dye eF780; anti-CD45-BV605;
anti-CD11b-BV421; anti-Ly6G-PECF594 and sorted on a FACSAria cell sorter (BD Bioscience) to obtain a highly purified neutrophils
population (purity > 99%).
Splenic T cells were MACS enriched with Pan T cell Isolation kit II (Miltenyi Biotec) according to manifacturer’s instructions, for
ex vivo stimulation with cytokines. Purity of the obtained CD3+ cells was > 99%. In some experiments, splenic T cells were
MACS enriched and subsequently T cell subsets (CD4+, CD8+, UTCab and gd T cells) were FACS-sorted. Resulting cells were pro-
cessed for mRNA extraction.
For RNA expression analysis on neutrophils, macrophages, immature macrophages and monocytes, tumor-associated CD11b+
cells were MACS-enriched (CD11b Microbeads, Miltenyi Biotec) according to manufacturer’s instructions. CD11b+ cells repre-
sented more than 85% of resulting cell suspension. Next, neutrophils, macrophages, immature macrophages and monocytes
were stained with LiveDead-Fixable Aqua, anti-CD45-BV605, anti-CD11b-BV786, anti-Ly6G-PECF594, anti-Ly6C-FITC, anti-F4/
80-PECy7, anti-CD64-PE, anti-CD11c-AlexaFluor700 and sorted on a FACSAria cell sorter (BD Bioscience) to obtain high purity
myeloid populations. Purity of each population was > 98%. Resulting cells were processed for mRNA extraction.e8 Cell 178, 346–360.e1–e11, July 11, 2019
For RNaseq experiments on T cell subset populations, tumor cells were depleted of CD11b+ cells and resulting cells were
stained with LiveDead-Fixable Aqua, anti-CD45-BV605, anti-CD11b-APCCy7, anti-TCRb-BV711, anti-TCRgd-BV421, anti-CD4-
AlexaFluor700 and anti-CD8-BV570 and sorted on a FACSAria cell sorter to obtain high purity T cell subset populations. Purity of
each population was > 98%. Resulting cells were processed for mRNA extraction.
For single cell RNaseq experiments on UTCab, tumor infiltrating leucocytes from Csf3r
+/+ and Csf3r/mice were MACS-enriched
(CD45+ TIL Microbeads), then CD11b+ cells and CD4+/CD8+ T cells were depleted. Cells were FACS-sorted as CD45+/CD11b-/
TCRb+/TCRgd-/CD4-/CD8- cells. Resulting cells (purity < 99.9%) were further processed for single cell RNaseq.
For the in vivo cotransfer experiments, splenic T cells were first MACS-enriched with Pan T cells Isolation kit II; after negative se-
lection of CD4-/CD8- T cells (CD4+/CD8+ T cells Microbeads, Miltenyi Biotec) cells were stained with fluorophore-conjugated anti-
bodies and DNT ab cells were FACS-sorted on a FACSAria as CD45
+/CD11b-/CD19-/TCRb+/TCRgd-/CD4-/CD8-/MR1-OP-RU-/
CD1d-aGal/Cer- cells. Cell purity was < 99.0%.
Cytokine Measurement
Tumors or 3-MCA injection sites were homogenized in 1 mL PBS/ containing protease inhibitors (Complete-EDTA-free; Roche)
and PMSF (1mM). Tissue homogenates were centrifuged at 14000 rpm for 30 min at 4C and supernatants were stored at 20C
for cytokine analysis. Murine IFNg, CCL2, CXCL1, CXCL2, CXCL12, M-CSF, G-CSF, TNFa, IL-22, IL-1b, IL-6, IL-12p70, VEGF,
TGFb and IL-23p19 were measured in tissue homogenates by ELISA (R&D DuoSet ELISA Development System) according to man-
ufacturer’s instructions. Murine IL-18, IL-17A were measured in tissue homogenates by ProcartaPlex Assay (ThermoFisher) accord-
ing to manufacturer’s instructions.
Immunohistochemistry
PFA-fixed, paraffin-embedded mouse tumor tissues were analyzed for each condition. Consecutive sections from the middle of the
tissue were used for histological examination in each mouse. Paraffin-embedded tissue sections were mounted on Super-frost
slides, dewaxed in xylene and rehydrated in ethanol. Endogenous peroxidase was blocked for 20 min in 90% ethanol containing
2% H2O2. Sections were then pretreated in a microwave oven (two cycles for 3 minutes each at 800 W, in 0.25 mM EDTA buffer).
Unspecific sites were blocked with Rodent Block M (Biocare Medical) 30 minutes and tissues were incubated for two hours with af-
finity-purified Ig against CD31 (Clone MEC13.3; BD Bioscience) in PBS supplemented with BSA (1%) and NP40 (0.02%). Envision+
SystemHRP Labeled Polymer anti Rabbit (Dako), Rat onMouseHRP-Polymer kit (BiocareMedical) was used as secondary antibody.
For anti-humanCD66b staining, paraffin embedded tissueswere cut at 3 mmand put over night at 37C. Then sectionswere dewaxed
in xylene and rehydrated in ethanol. Antigen unmasking was performed in Decloaker Chamber in DIVA Buffer (BiocareMedical) (3 mi-
nutes at 125C, 5minutes at 90C). Endogenous peroxidasewas blockedwith H2O2 2% for 20minutes. Unspecific binding sites were
blocked with Background Sniper (Biocare Medical) for 15 minutes. Mouse anti-human CD66b (Clone G10F5; BD PharMingen, CA) or
control antibody was diluted in Washing Buffer (PBS pH 7.00 + 0.05% Tween 20) and incubated in humid chamber 1h. MACH 1 HRP
polymer (Biocare Medical) was used as secondary antibody. After washing, slides were developed with DAB (3,30-diaminobenzidine)
(Biocare Medical) and counterstained with Hematoxilyn. Tissues were dehydrated with ethanol, mounted with Eukitt and analyzed
with an Olympus BX61 virtual slide scanning system. The number of CD66b+ cells infiltrating the tumors was determined in whole
tissue sections (magnification 20X) and mean values were employed to divide tumors in CD66bhigh and CD66blow.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis
For animal studies, sample size was defined on the basis of past experience on cancer models, to detect differences of 20% or
greater between the groups (10% significance level and 80% power). Values were expressed as mean ± s.e.m. Wilcoxon
matched-pairs signed-rank test was used to compare two groups for tumor incidence. Friedman test with Dunn’s multiple compar-
ison was used to compare tumor incidence for multiple group experiments. One-way ANOVA or Kruskal-Wallis test were used to
compare multiple groups. Two-tailed multiple Student’s t test was used to compare unmatched groups with Gaussian distribution.
Two-tailed Mann–Whitney U-test was used to compare unmatched groups with non-Gaussian distribution. The Kaplan-Meier
method was used for survival curve analysis, and the log-rank (Mantel-Cox) test was used to determine the statistical significance.
p% 0.05 was considered significant. A ROUT test was applied to exclude outliers. Statistics were calculated with GraphPad Prism
version 7, GraphPad Software.
30-mRNA Sequencing analysis
Raw reads were preprocessed for adaptor trimming and quality check was assessed using the FastQC tool (http://www.
bioinformatics.babraham.ac.uk/projects/fastqc). Reads were aligned to the reference genome (Ensembl Mouse release GRC38)
using the STAR (Dobin et al., 2013) algorithm. To minimize the variability among replicates, a coefficient of variation (CV) was calcu-
lated based on TMM (TrimmedMean ofM-Values) normalized expression values in each group. Genes exceeding 100%CV in at least
one replicate’s group were not considered for further differential expression analysis. Differential expression analysis was performed
using the GLM approach implemented in the R/Bionconductor (Gentleman et al., 2004) edgeR (Robinson et al., 2010) packageCell 178, 346–360.e1–e11, July 11, 2019 e9
(p value% 0.001). Results of differential analysis are provided in Table S2. The resulting gene lists were analyzed through the use of
Ingenuity Pathways Analysis (IPA) (Kra¨mer et al., 2014). Results of IPA analysis are provided in Table S3.
Single cell RNA sequencing analysis
Raw sequencing data in the format of bcl files were converted in fastq files and aligned to the mouse reference genome [http://cf.
10xgenomics.com/supp/cell-exp/refdata-cellranger-mm10-1.2.0.tar.gz] taking advantage of the Cell Ranger Pipeline version 2.1,
provided by 10X Genomics. Raw digital gene expression matrix (unique molecular identifier (UMI) counts per gene per cell) were
analyzed using the Seurat R package version 2.3.0 with default parameters. To assess the correlation between biological replicates
in each condition we computed a Pearson correlation analysis using normalized gene expression matrices (Figure S5L-M). Based on
high correlation between replicates, samples belonging to each condition were pooled together using the Cell Ranger aggregate op-
tion producing a unique raw digital gene expression matrix in Csf3r/ and Csf3r+/+ conditions. Pooled data were imported into the
Seurat pipeline and filtered applying the following thresholds: less than 200 ormore than 3500 as unique expressed genes, more than
20000 as the number of UMIs and 10% as the percentage of mitochondrial genome content (forCsf3r+/+ condition) and less than 200
or more than 4000 as unique expressed genes, more than 20000 as the number of UMIs and 10% as the percentage of mitochondrial
genome content (forCsf3r/ condition). Cell cycle phases were predicted and corrected in each dataset using a Seurat function that
scores each cell based on the expression of canonical marker genes for S and G2/M phases. The resulting dataset was normalized
through a global-scaling method, converted by a scale factor (10,000 by default) and log-transformed using the ScaleData Seurat
implemented function. A canonical correlation analysis was run in order to identify common sources of variation between the two
datasets, using the RunCCA implemented function that stores into a single object the canonical correlation vectors. Finally an inte-
grated analysis of the two datasets was performed choosing a number of 30 correlation components. The resulting data were sub-
jected to clustering analysis using standard Seurat package procedures. A validation consistency procedure of the resolution (using
the ValidateCluster function) allowed us to select 0.6 as the suitable resolution level. The total 12 identified clusters were visualized
using t-distributed Stochastic Neighbor Embedding of the principal components (t-SNE) as implemented in Seurat.
Average gene expression matrices were retrieved for each cluster and a Spearman correlation analysis was performed, using the
Picante R package version 1.6-2. Differential expression analysis among clusters (using the FindAllMarkers implemented function,
with parameters only.pos = FALSE,min.pct = 0.2, thresh.use = 0.2) allowed us to select the topmarkers expressed at a higher level by
each cluster.
Pathway enrichment analysis examining enriched processes in clusters was performed using Gene Set Variation Analysis (GSVA)
software (Ha¨nzelmann et al., 2013) from Bioconductor (version 3.8). Mouse_AllPathways_November_01_2018_symbol.gmt from
[http://download.baderlab.org/EM_Genesets/current_release/] was used to identify enriched cellular pathways in GSVA.
Single-cell trajectory analysis
Monocle (Qiu et al., 2017; Trapnell et al., 2014) was used to investigate transcriptional and functional trajectories concerning the
twelve clusters identified with Seurat (see Cell clustering, differential expression and pathway analysis paragraph). Using the
reversed graph embedding approach, Monocle learns the kinetics of gene expression and places each cell along an inferred trajec-
tory. The data, in the format of raw data, together with clusters information deriving from Seurat, were loaded into a Monocle
object. Normalization and dimensionality reduction were performed using default parameters. The trajectory was designed using
the plot_cell_trajectory command. Cells were ordered along an artificial trajectory based on gene expression changes among
clusters. Genes that underwent a significant change along pseudotime (q-value < 0.05) were visualized by a heatmap using
plot_pseudotime_heatmap. The trend of Klra1, Klra6, Klra7 and Klrd1 gene expression was depicted by individual graphs using
the plot_genes_in_pseudotime function.
Public gene expression data analysis
Publicly available RNA sequencing data were downloaded from the Cancer Genome Atlas database (TCGA) through the Firebrowse
repository (http://firebrowse.org/; release 01/28/2016), for Sarcoma dataset (SARC) and from Xena Browser (https://xenabrowser.
net/) for Melanoma dataset (SKCM).
The sarcoma dataset included a total of 261 tumor samples, classified in the following subtypes: dedifferentiated liposarcoma
(n = 58), desmoid tumor (n = 2), giant cell sarcoma (n = 1), leiomyosarcoma (lms, n = 104), malignant peripheral nerve sarcoma (mpnst,
n = 10), myxofibrosarcoma (n = 25), synovial sarcoma (n = 10), undifferentiated sarcoma (ups, n = 51). Sarcoma histotypes with a total
number of samples < 10were excluded from further analysis. TheMelanoma dataset included a total of 474 patients. RSEM (RNASeq
by Expectation-Maximization) expression values were retrieved and log-transformed. For colorectal cancer (CRC) cohort we used a
microarray dataset (GEO: GSE24551) including a total of 160 samples. For ovarian cancer we used a microarray dataset (GEO:
GSE32062) including a total of 270 samples, from which we selected the high grade cohort (128 samples). For both datasets we
used respectively Robust Multi-array Average (RMA) and Normalized Signal Intensity (NSI) gene expression values as provided
by GEO.
Survival analysis was performed with GraphPad PrismTM using the Kaplan-Meier (KM) approach and applying the Log-rank
(Mantel-Cox) test to estimate survival curves comparison. For CSF3R survival analysis, the median gene expression value was
used to classify tumor samples into CSF3Rlow and CSF3Rhigh gene expression groups. A signature of 31 neutrophil-related genese10 Cell 178, 346–360.e1–e11, July 11, 2019
was retrieved from Bindea et al. (Bindea et al., 2013) (Table S6). This neutrophil-specific gene signature was based on previous
microarray datasets of gene expression in resting and activated human peripheral blood leukocyte subsets (Chtanova et al.,
2005). In particular, the signature is composed of genes with higher expression in resting and LPS-activated neutrophils compared
to any other leukocyte subset. Of note, CSF3R was included in the neutrophil signature and, in the TCGA dataset of UPS patients, a
significant correlation was observed between CSF3R expression and 28 out of 30 genes present in the neutrophil signature (not
shown). Type 1 immune response gene signature was designed by including factors known to be upstream or downstream of
IFNG signaling pathway (genes listed in Table S6) (Ayers et al., 2017; Ikeda et al., 2002; Murphy et al., 2000; Swain et al., 2012). Their
expression correlated with IFNG (p < 0.005, not shown). For both signatures, RSEM or normalized signal values were converted into
z-score applying the following transformation: z-score = (X – average(X))/stdev(X), where X represents gene expression values. The
average and standard deviation were calculated considering the expression of X across all tumor samples, as previously described
(Chao et al., 2016). Finally, the median z-score value was considered as the threshold to define Low and High expression groups.
Statistics and reproducibility
Figures 1A and 1B, n = 10mice per group; Figure 1C, n = 20 (Csf3r+/+), n = 8 (Csf3r/), n = 12 (Csf3r/ + Nf). Figures 1A and 1B, one
representative experiments out of twenty performed; Figure 1C, pooled data of two independent experiments performed.
Figure 2A, n = 9 mice per group; Figures 2B and 2C, n = 8 (Csf3r+/+ isotype), n = 9 (Csf3r+/+ anti-CD115), n = 9 (Csf3r/ isotype) or
n = 10 (Csf3r/ anti-CD115) mice per group, Figure 2D, n = 5 (Csf3r+/+), n = 5 (Csf3r/), n = 4 (Csf3r/ + Nf); Figure 2E, n = 10
(Csf3r+/+), n = 10 (Csf3r/), n = 4 (Csf3r/ + Nf) Figure 2F, n = 9 mice per group; Figures 2A–2F, one experiment performed.
Figure 3A, n = 12 (Csf3r+/+) or n = 18 (Csf3r/) mice; Figure 3C, n = 16 (Csf3r+/+) or n = 21 (Csf3r/) mice; Figure 3D, n = 5 (Csf3r+/+),
n = 14 (Csf3r/), n = 5 (Csf3r/+neutrophils); Figure 3E, n = 11 (Csf3r+/+), n = 14 (Csf3r/), n = 14 (Csf3r/ + neutrophils) mice;
Figure 3F, n = 9 (Csf3r+/+), n = 20 (Csf3r/) mice per group, Figure 3G, n = 5 (Csf3r+/+), n = 14 (Csf3r/), n = 5 (Csf3r/ + NF)
mice per group. Pooled data of two (Figures 3A, 3C, 3E, and 3F) experiments are shown. Figures 3D and 3G, one experiment
performed.
Figure 4A, n = 4mice per group; Figures 4B and 4C, n = 4mice per group; Figure 4D, n = 3mice per group; Figure 4E, n = 6 (Csf3r+/+
isotype), n = 7 (Csf3r+/+ anti-iL-12p70), n = 5 (Csf3r/ isotype) or n = 4 (Csf3r/ anti-iL-12p70) mice per group; Figure 4G, n = 5 (Mf),
n = 5 (Nf), n = 8 (Mf+Nf), n = 3 (Mf+Nf Transwell); Figure 4H, n = 4mice per group; Figure 4I, n = 10mice per group. Figures 4A–4F,
one experiment performed. Pooled data of two (Figures 4G and 4H) or three (Figure 4I) experiments are shown.
Figures 5A–5E, n = 2 mice per group; Figures 5F and 5G, n = 5 mice per group. Figures 5A–5E, one experiment performed.
Figures 6A–6D, n = 2 mice per group; Figures 6E and 6F, n = 5 mice per group; Figure 6G, n = 8 (Csf3r+/+), n = 7 (Csf3r+/+ + DNTab);
Figure 6H, n = 8 (Csf3r+/+), n = 7 (Csf3r+/+ + DNTab). Figures 6A–6H, one experiment performed.
DATA AND SOFTWARE AVAILABILITY
Data availability and accession
The accession number for the bulk RNA-sequencing data reported in this paper is Gene Expression Omnibus (GEO) (https://www.
ncbi.nlm.nih.gov/geo/): GSE109031. The accession number for the single cell RNA-sequencing data reported in this paper is Gene
Expression Omnibus (GEO): GSE123508.
The authors declare that all other data supporting the findings of this study are available within the article and its supplementary
information files.
Reagent availability
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Supplemental Figures
Figure S1. Neutrophil Deficiency in Csf3r/Mice and Neutrophil Depletion in Csf3r+/+Mice Increase Induction of 3-MCA-Sarcomagenesis,
Related to Figure 1
(A) Absolute counts of main leukocyte populations in peripheral blood of healthy Csf3r+/+and Csf3r/mice.
(B) Csf3r+/+and Csf3r/ sarcoma weight of mice sacrificed at the same time point (120 days after 3-MCA injection).
(C-G) Tumor incidence of 5 representative experiments of 3-MCA induced sarcomas in Csf3r+/+and Csf3r/mice conducted over a period of 4 years.
(H) Incidence of 3-MCA induced sarcomas in Csf3r+/+ and Csf3r/ mice bred separately or in cohousing conditions.
(I) Incidence of 3-MCA induced sarcomas in bone marrow chimeras (donor > recipient). (
(J) Incidence of 3-MCA-induced sarcomas in Csf3r+/+ and Csf3r/ mice treated with anti-Ly6G antibody or with isotype control.
(K) Representative dot plots showing the purity of naive neutrophils used in adoptive transfer experiments, gated on total isolated cells.
(A-B) Data are mean ± SEM. *p% 0.05, **p% 0.01 ***p% 0.001, ns, not statistically significant. (A) Two-tailed multiple Student’s t tests. (B) Two-tailed Mann-
Whitney U test. (C-G), (J) Wilcoxon matched-pairs signed ranked test. (H-I) Friedman test with Dunn’s multiple comparison test.
(A) n = 4 (Csf3r+/+) or n = 5 (Csf3r/) mice. (B) n = 27 (Csf3r+/+) or n = 31 (Csf3r/) mice. (C-G) n = 8-10mice per group. (H) n = 8 (Csf3r+/+ separate), n = 12 (Csf3r/
separate), n = 5 (Csf3r+/+ cohoused), n = 8 (Csf3r/ cohoused) mice. (I) n = 11 Csf3r+/+ > Csf3r/, n = 12 Csf3r/ > Csf3r/, n = 13 Csf3r/ > Csf3r+/+, n = 14
Csf3r+/+ > Csf3r+/+. (J) n = 8 (Csf3r+/+ isotype) or n = 9 (Csf3r/ anti-Ly6G) mice. (A-J) One experiment performed. (B) Pooled data of four independent ex-
periments. (C-G) 5 experiments out of twenty conducted over a period of 4 years.
(legend on next page)
Figure S2. TANs inCsf3r+/+Mice Display an Activated Phenotype; Role of Macrophages in the Increased Susceptibility ofCsf3r/ to 3-MCA
Sarcomagenesis, Related to Figures 1 and 2
(A-C) Number of sarcoma-infiltrating CD45+ cells (A), leukocyte cell subset frequencies (B) and absolute numbers (C) assessed by flow cytometry (tumor
volumey 2000 mm3).
(D-F) Quantification by flow cytometry of CD11b, CD54 and CD62L expression in TANs and peripheral-blood neutrophils from Csf3r+/+ sarcoma-bearing mice.
(G) mRNA gene expression in purified TANs. Gene expression was relative to Gapdh expression and normalized on the mean expression in naive bone marrow
neutrophils (BM NF).
(H) Proliferative activity of tumor-infiltrating myeloid subsets, assessed by flow cytometry (intracellular EdU staining).
(I) Gating strategy for tumor-associated non-granulocytic myeloid populations. Cells represented in left dot plot are pregated on Aqua-/CD45+/Ly6G- cells.
(J-K) Flow cytometry analysis of CD206 and CD11c expression on tumor-associated non-granulocytic myeloid cells
(L) mRNA expression of M1- and M2-selected genes in tumor-infiltrating TAMs. Gene expression was relative to Gapdh expression and normalized on the mean
of expression found in Csf3r+/+ TAMs.
(M-N) Immunohistochemical analysis and relative quantification of CD31+ cells in Csf3r+/+ and Csf3r/ sarcomas. 5 random fields per sample were counted.
Scale bar, 100 mm.
(O-R, mRNA expression of M1- andM2-related genes in BMDMs generated withM-CSF (O-P) or GM-CSF (Q-R) (seeMethods). Gene expression was normalized
on Gapdh expression.
(S) Representative dot plots showing depletion of TAMs after treatment with anti-CD115 antibody. (T) Incidence of 3-MCA-induced sarcomas in Csf3r+/+ and
Csf3r/ mice treated with anti-CD115 antibody or with isotype control.
(A-F), (H), (J-K), (N-R). Data aremean ± SEM. *p% 0.05, **p% 0.01 ***p% 0.001, ns, not statistically significant. (A), (D-F). Two-tailedMann-WhitneyU test. (B-C),
(H), (J-K), (O-R) Two-tailed multiple Student’s t tests. (G), (L) Wilcoxon signed rank test. (T) Friedman test with Dunn’s multiple comparison test.
(A) n = 21 mice per group. (B) n = 6 Csf3r+/+ eosinophils, basophils, n = 8 Csf3r/ eosinophils, basophils, n = 14 Csf3r+/+ T, NK cells, n = 9 Csf3r/ T, NK cells,
n = 9Csf3r+/+B cells, n = 6Csf3r/B cells, n = 17Csf3r+/+ TANs, monocytes, TAMs, immature TAMs, n = 20Csf3r/ TANs, monocytes, TAMs, immature TAMs.
(C) n = 6Csf3r+/+ eosinophils, basophils, n = 8Csf3r/ eosinophils, basophils, n = 18Csf3r+/+ T, B, NK cells and TAMs, n = 19 TANs,monocytes, n = 20Csf3r/B
cells, n = 21 Csf3r/ NK, T cells, n = 23 Csf3r/ TANs, monocytes, immature TAMs, TAMs. (D-F) n = 6 TANs, n = 8 blood neutrophils. (G) n = 5 Il1b, Met, n = 6
Il27p28,Ccl5,Ccl2, n = 9Nos2, Arg, Tnfa, n = 11 Ifng, Ccl3, n = 12Cxcl10. (H) n = 6 (Csf3r+/+) or n = 9 (Csf3r/) mice. (J-K) n = 5mice. (L) n = 3 (Cxcl10, Il23a, Ifng),
n = 7 (Retnla), n = 8 (Chil3), n = 9 (Arg1, Stab1,Mrc1, Msr1, Il4ra), n = 10 (Ccr3, Nos2, Il10, Tgfb1). (M-N) n = 7 (Csf3r+/+) or n = 9 (Csf3r/) mice. (O-P) n = 4mice per
group. (Q-R), n = 8 (NT, IL-4, IL-4 + G-CSF, IFNg), n = 7 (G-CSF), n = 4 (IFNg+G-CSF). (H) n = 7 (Csf3r+/+ Isotype, Csf3r/ Isotype, Csf3r/ anti-CD115) or n = 8
(Csf3r+/+ anti-CD115) mice per group.
(A-C) Pooled data of four experiments are shown. (D-H), (M-N). (S-T) One experiment performed. (J-L) Pooled data from two (J-K) or three (L) experiments are
shown. (O-R) Pooled data from two experiments.
Figure S3. The Polarization of Conventional T Cells Is Not Altered in Csf3r/ Mice, Related to Figure 3
(A) Ifng mRNA expression determined by qPCR on sorted leukocyte subsets from Csf3r+/+ sarcomas. Gene expression was normalized on Gapdh expression.
(B) Gating strategy used for tumor-infiltrating T cell subset characterization. Left panel represents Live/CD45+ cells.
(C) Expression of Eomes, Rorgt and T-bet in splenic UTCab from sarcoma-bearing Csf3r
+/+ and Csf3r/ mice.
(D) Expression of Eomes, Rorgt and T-bet in CD4+, CD8+ ab T cells and gd T cells infiltrating Csf3r+/+ and Csf3r/ sarcomas.
(E) Expression of Eomes, Rorgt and T-bet in CD4+, CD8+ ab T cells and gd T cells infiltrating Csf3r+/+ and Csf3r/ sarcomas after neutrophil adoptive transfer.
(F) Expression of IL-17A by tumor-infiltrating T cells stimulated ex vivo by PMA plus ionomycin.
(G) Frequency of ILC1 subsets infiltrating Csf3r+/+ and Csf3r/ sarcomas determined by flow cytometry.
(H) Maturation-related subset frequency within cNK cells infiltrating Csf3r+/+ and Csf3r/ sarcomas, determined by flow cytometry.
(I) Expression of Eomes, Rorgt and T-bet in UTCab, CD4
+ and gd T cells infiltrating the 3-MCA injection site (10 days after administration of 3-MCA) after neutrophil
adoptive transfer. CD8+ T cell polarization state could not be evaluated due to their low frequency in the tissue.
(legend continued on next page)
(J) Frequency of T cell subsets infiltrating 3-MCA injection site (10 days after 3-MCA administration).
(A), (C-J) Data are mean ± SEM. *p% 0.05, **p% 0.01, ***p% 0.001; ns, not statistically significant. (A), (C), (F-H), (J) Two-tailed multiple Student’s t tests. (E, I)
Kruskal-Wallis test with Dunn’s multiple comparison test.
(D-E) 3x106 neutrophils were i.v. transferred once a week starting from the first day the tumor was palpable.
(I-J) 3x106 neutrophils were i.v. transferred at days 1, 0, 1 and 9 with respect to 3-MCA administration.
(A) n = 5 (TAN, Monocytes), n = 6 (Immature Monocytes, T cells), n = 7 (TAMs). (C) n = 5 (Csf3r+/+) or n = 3 (Csf3r/) mice. (D) n = 16 (Csf3r+/+) or n = 21 (Csf3r/)
mice. (E) n = 5 (Csf3r+/+), n = 14 (Csf3r/), n = 5 (Csf3r/ + neutrophils) mice. (F) n = 10 (Csf3r+/+) or n = 18 (Csf3r/) mice. (G-H) n = 7 (Csf3r+/+) or n = 5 (Csf3r/)
mice; i, n = 12 (Csf3r+/+), n = 14 (Csf3r/), n = 12 (Csf3r/ + Nf) mice. (J) n = 23 mice per group.
(A), (C), (E), (G-H) One experiment performed. Pooled data from two (D, I) or three (F, J) experiments are shown.
Figure S4. Frequency and Polarization of MAIT and iNKT Cells Are Not Altered in Csf3r/ Mice, Related to Figures 3 and 4
(A-B) Representative histogram and relative quantification of Plzf expression in tumor-infiltrating Csf3r+/+ and Csf3r/ UTCab, assessed by flow cytometry.
(C) Representative dot plots from a Csf3r/ sarcoma. Expression of CD4 and CD8 on tumor-infiltrating iNKT and MAIT cells.
(D) Representative plots showing iNKT, MAIT and DNTab frequencies among sarcoma-infiltrating UTCab in Csf3r
+/+ and Csf3r/ mice.
(E-F) Expression of Eomes, Rorgt and T-bet in sarcoma-infiltrating iNKT and MAIT cells after adoptive neutrophil transfer.
(G-I) Expression of Eomes, Rorgt and T-bet in UTCab, iNKT and MAIT cells at the 3-MCA injection site (10 days after 3-MCA administration) after adoptive
neutrophil transfer.
(J) iNKT, MAIT and DNTab frequencies among CD45
+ cells infiltrating the 3-MCA injection site (10 days after administration of 3-MCA) in Csf3r+/+and
Csf3r/ mice.
(K-L) Representative dot plots (K) and quantification (L) of iNKT, MAIT and DNTab frequencies among CD45+ cells in dorsal skin of healthy Csf3r
+/+and
Csf3r/ mice.
(M-N) Representative histograms (M) and relative quantification (N) of Rorgt expression in iNKT, MAIT and DNTab cells from dorsal skin of healthy Csf3r
+/+and
Csf3r/ mice.
(B), (E-J), (L), (N) Data are mean ± SEM. ***p% 0.001; *p% 0.05; ns, not statistically significant. (B), (J), (L), (N) Two-tailed multiple Student’s t tests. (E), (F), (I)
Kruskal-Wallis test with Dunn’s multiple comparison test. (G-H) One-way ANOVA.
(legend continued on next page)
(E-F) 3x106 neutrophils were i.v. transferred once a week starting from the first day the tumor was palpable.
(G-I) 3x106 neutrophils were i.v. transferred at days 1, 0, 1 and 9 with respect to 3-MCA administration.
(B) n = 16 (Csf3r+/+) or n = 21 (Csf3r/) mice. (E-F) n = 5 (Csf3r+/+), n = 14 (Csf3r/) or n = 5 (Csf3r/ + neutrophils). (G-I) n = 6 (Csf3r+/+), n = 7 (Csf3r/) or n = 7
(Csf3r/ + Nf) mice. (J) n = 6 (Csf3r+/+), n = 7 (Csf3r/) mice. (L), (N) n = 7 mice per group.
(B) Two pooled experiments. (E-J), (L), (N) One experiment performed.
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(legend on next page)
Figure S5. UTCab from Csf3r
+/+ Mice Show High Expression of Type 1 Immune Response-Related Genes and Are Responsive to IL-12,
Related to Figures 4 and 5
(A) Diagram showing predicted upregulated and downregulated biological pathways using IPA software on Csf3r/ tumor-associated UTCab, compared to
Csf3r+/+ tumor-associated UTCab. (red: upregulated pathways; blue: downregulated pathways). Associated p-value is shown for each pathway.
(B) RNA-seq analysis of tumor-infiltrating T cell subsets isolated fromCsf3r+/+mice. Differentially expressed genes (p% 0.001) in UTCab comparedwith gd T cells,
CD4+ and CD8+ T cells are shown. Scale bar representing expression z-score in shown on the left.
(C) Relative expression of Ifng mRNA in Csf3r+/+ T cell subsets determined by bulk RNA-seq.
(D) Predicted upstream regulators in tumor-infiltrating Csf3r+/+ UTCab compared with other tumor-infiltrating Csf3r
+/+ T cell subsets, generated by IPA analysis;
Associated p-value is shown for each regulator.
(E) Expression of Eomes, Rorgt and T-bet in gd T cells infiltrating the 3-MCA injection site after treatment with IL-12p70-neutralizing antibody or isotype control.
(F) Representative gating strategy for identification of splenic Csf3r+/+ DNTab cells.
(G) IL-12p70 levels detected by ELISA in supernatants of BMDM-neutrophil cocultures after stimulation with GM-CSF+STING agonist cAIMP.
(H-K) Frequency of indicated UTCab subsets within total pool of tumor-infiltrating UTCab cells in Csf3r
+/+ and Csf3r/ mice analyzed by scRNaseq and by flow
cytometry.
(L) t-SNE projections showing overlap between Csf3r+/+ and Csf3r/ biological replicates.
(M) Pearson correlation analyses of total gene expression averages between the 2 biological replicates across Csf3r+/+ and Csf3r/ conditions.
(C, E, G–K) Data are mean ± SEM. ***p% 0.001; **p% 0.01; *p% 0.05; ns, not statistically significant. (E) One-way ANOVA, (G) two-tailed Student’s t test.
(C) n = 4 per group. (E) n = 6 (Csf3r+/+ isotype), n = 6 (Csf3r/ isotype), n = 6 (Csf3r+/+ anti-iL-12p70), n = 5 (Csf3r/ anti-iL-12p70). (G) n = 3, (H-K) (flow cytometry
data), n = 6 Csf3r+/+, n = 14 Csf3r/. (H-K) (scRNaseq data), pooled data from n = 2 Csf3r+/+ and n = 2 Csf3r/ mice.
(A-E, G-M) One experiment performed.
(legend on next page)
Figure S6. Functional Characterization of Sarcoma-Infiltrating UTCab As Assessed by scRNA-Seq, Related to Figures 5 and 6
(A) Heatmap representing Spearman correlations among the twelve clusters identified, according to their transcriptional profiles. Green and red dashed boxes
highlight the two functionally distinct cluster groups (red: type 1, abundant in Csf3r+/+ sarcomas; green: type 3, abundant in Csf3r/ sarcomas).
(B) Heatmap showing GSVA enrichment score of selected pathways in clusters 1-12. Clusters are ordered according to their transcriptional similarity.
(C-F) Heatmaps displaying expression of selected genes related to migration capacity (C), proliferation (D), checkpoint and costimulatory molecules (E) and
cytolytic mediators (F). UTCab cluster order is guided by gene expression. Green, red, blue and purple dashed boxes highlight the different functionally distinct
cluster groups and are referred to in the main text.
(G) Heatmap of differentially expressed genes, ordered according to their common expression variation through pseudotime (gene sets 1-6). Selected genes
belonging to each gene set are highlighted on the right.
(A-G) n = 2 mice per group. Scale bars showing Spearman correlation coefficient (A), GSVA enrichment score (B) or gene expression score (C-G) are provided.
One experiment performed.
(legend on next page)
Figure S7. Clinical Significance of TAN Infiltration and Type 1 Immune Response in Soft Tissue Sarcoma Subtypes and Selected Human
Tumors, Related to Figure 7
(A) Kaplan-Meier curve of recurrence-free survival in UPS patients from TCGA cohort.
(B-M) Kaplan-Meier overall survival curves of patients from TCGA cohort with dedifferentiated liposarcoma, leiomyosarcoma andmyxofibrosarcoma with high or
low expression of (B-D)CSF3R, (E-G) TAN gene signature (31 genes), (H-J) IFNG and (K-M) 12 genes related to type 1 immune response within tumor specimens.
(N-U) Kaplan-Meier survival curves of patients of ovarian cancer (N-Q) and skin cutaneous melanoma (R-U) with high or low expression of CSF3R, TAN gene
signature, IFNG and type 1 immune gene signature within tumor specimens.
(V-W) Pearson correlation between CSF3R and IFNG expression in ovarian cancer and melanoma patients. Gene expression is reported as NSI or as RSEM,
respectively (see Methods).
Gene lists used for type 1 immune response and neutrophil signatures are shown in Table S6.
(A-W) Numbers depicted in each graph represent the total number of patients analyzed.
(A-U) p and HR, Hazard Ratio (95% CI ratio) were calculated with log-rank (Mantel-Cox) test. (V-W) Pearson correlation.
